

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 August 2005 (18.08.2005)

PCT

(10) International Publication Number
WO 2005/075480 A1

- (51) International Patent Classification⁷: **C07D 487/04**,
417/12, 417/04, 277/34, A61K 31/4188, 31/427
- (74) Agents: **DE JUSTO, V., Jorge et al.**; c/o Jacobacci &
Partners, M. & J. de Justo, Castellana 128, E-28046 Madrid
(ES).
- (21) International Application Number:
PCT/EP2005/000840
- (22) International Filing Date: 28 January 2005 (28.01.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
P 200400205 30 January 2004 (30.01.2004) ES
- (71) Applicant (for all designated States except US): **CEPA
SCHWARZ PHARMA S.L.** [ES/ES]; Paseo de la Castel-
lana 141, E-28046 Madrid (ES).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **LOPEZ RO-
DRIGUEZ, Maria, Luz** [ES/ES]; Rector Royo Villanova
10, E-28040 Madrid (ES). **BENHAMU SALAMA,**
Bellinda [ES/ES]; Valdeparra 76, E-28100 Alcoben-
das, Madrid (ES). **DEL RIO ZAMBRANA, Joaquin**
[ES/ES]; Irunlarrea 13, E-31008 Pamplona, Navarra
(ES). **FRECHILLA MANSO, Diana** [ES/ES]; Amaya
24, E-31004 Pamplona, Navarra (ES). **MARCO MAR-
TINEZ, Isabel** [ES/ES]; Pedro Rico 11, E-28029 Madrid
(ES).
- (81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.
- (84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIAZA- OR THIAZADIONE DERIVATIVES WITH NEUROPROTECTIVE ACTIVITY

(57) Abstract: The present invention relates to certain derivatives of cycloalkanediones invariably substituted with a chroman-2-yl, 2-quinolyl or -O-phenyl residue which are serotonin (5-hydroxytryptamine, 5-HT) 5-HT_{1A} receptor subtype agonists modulators, to their stereochemical isomers and to their use in the preparation of a medicament for the treatment of pathological states for which an agonist a modulator of these receptors is indicated.

WO 2005/075480 A1

DIAZA- OR THIAZHADIONE DERIVATIVES WITH WITH NEUROPROTECTIVE ACTIVITY


FIELD OF THE INVENTION

5

The present invention relates to certain derivatives of cycloalkanediones invariably substituted with a chroman-2-yl, 2-quinolyl or -O-phenyl residue which are serotonin (5-hydroxytryptamine, 5-HT) 5-HT_{1A} receptor subtype agonists modulators, to their stereochemical isomers and to their use in the preparation of a medicament for the treatment of pathological states for which an agonist a modulator of these receptors is indicated.

BACKGROUND OF THE INVENTION

PCT/ES03/00394 discloses cycloalkanedione derivatives of general formula Ia:



25

wherein:

R₁ is selected from the group formed by H, -(CH₂)₃-, -(CH₂)₄-, -CH₂-S-CH₂-, -S-CH₂-CH₂-;

R₂ is selected from the group formed by N, S;

n has a value of 0 or 1;

30

Z is selected from the group formed by C₂-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl;


R₃ is selected from the group formed by H, C₁-C₁₀-alkyl, aryl, aralkyl;

m has a value of 0 to 2;

R₄ is selected from the group formed by O, CH₂;

35

R₅ is selected from the group formed by:



wherein:

R_6 is selected from the group formed by H, C_1 - C_5 -alkyl, C_1 - C_5 -alkoxy, OH, F, Cl, Br, I;

X is selected from the group formed by O, S, NH, NCH_3 ;

Y is selected from the group formed by O, NH;

W is selected from the group formed by S, NH.

PCT/ES03/00394 describes radioligand displacement tests to characterize the *in vitro* affinity and selectivity in the 5-HT_{1A} cerebral receptors of some of the possible compounds represented by the previous Markush formula (Ia), whilst the functional character (agonist / antagonist) was determined by the study of their effect on adenylate cyclase in HeLa cells transfected with the human 5-HT_{1A} receptor, measuring their inhibiting effect on the stimulation of the enzyme induced by forskolin for the compounds:

- 2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (a)
- 2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-b]thiazole, (b)
- 2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-c]thiazole, (c)
- 3-[4-[(Chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine, (d)

- 2-[4-[2-(Phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (e)

For these compounds (a, b, c, d, e), an in vivo functional characterization test was performed by the quantification of the hypothermia associated to the stimulation of the receptor. Furthermore, the neuroprotective effect was evaluated by in vitro experimental models using primary cultures of rat hippocampus exposed to serum deprivation (compounds a, d, and e), to a toxic concentration of glutamate (compound a), or incubated in conditions of hypoxia and absence of glucose (compound a). On the other hand, the determination of the in vivo neuroprotective action is evaluated both in the transient global ischemia model in gerbils (compounds a and e) and in the permanent focal ischemia model in rats (compound a).

SUMMARY OF THE INVENTION


The present invention relates to a group of cycloalkanedione derivatives which are invariably substituted with a chroman-2-yl residue, a 2-quinolyl residue or an -O-phenyl residue.

In extensive studies the inventors have surprisingly identified a class of compounds with a high affinity for the 5-HT_{1A} receptor and remarkable neuroprotective properties.

The 5-HT_{1A} affinity has been demonstrated by in vitro radioligand displacement tests. Likewise, their affinity for the serotonergic 5-HT_{2A}, 5-HT₃, 5-HT₄ and 5-HT₇ receptors, 5-HT transporter, adrenergic α_1 and dopaminergic D₂ receptors have been characterized. The functional character (agonist/antagonist) of the new ligands was studied, determining the inhibition of the stimulating effect of forskolin on adenylate cyclase and studying, furthermore, in vivo, the 5-HT_{1A} agonist character of the new compounds by hypothermia analysis. In the same way, the compounds of the present invention have shown in vitro neuroprotective action on primary cultures of rat hippocampus, considering those models of neuronal death (deprivation of trophic factors and deprivation of oxygen and glucose) wherein the serotonergic 5-HT_{1A} agonists are more effective. The protective effect was also studied for cerebral infarction induced by permanent occlusion in the middle cerebral artery

in rats.

According to a first aspect of the present invention, it relates to compounds of the general formula I:



their stereochemically isomer forms, hydrates, solvates and pharmaceutically acceptable salts thereof, wherein:

R_1 and R_2 are H or are methylene groups bound together forming with the heterocyclic ring a 5- or 6- membered ring; if $R_4=S$ then R_1 is H and R_2 is absent;

R_4 is selected from the group consisting of N and S;

n being an integer from 0 to 1;

X is selected from the group consisting of C_2 - C_{10} -alkyl, C_2 - C_{10} -alkenyl and $-CH_2-$ Y- CH_2- ; wherein Y is phenyl;

m being an integer from 1 to 2;

R_3 is selected from the group consisting of chroman-2-yl, 2-quinolyl and -O-phenyl, wherein the aromatic ring of the chromanyl moiety, the quinolyl or the phenyl residue is optionally substituted by one or more groups chosen from C_1 - C_6 -alkoxy, C_1 - C_6 -alkyl, halogen, C_2 - C_6 -alkenyl, halo- (C_1-C_6) -alkyl, halo- (C_1-C_6) -alkoxy, phenyl, phenyl(C_1-C_6)-alkyl, phenoxy, C_1 - C_6 -alkylcarbonyl, phenylcarbonyl, phenyl(C_1-C_6)alkylcarbonyl, C_1 - C_6 -alkoxycarbonyl, phenyl(C_1-C_6)alkoxycarbonyl, C_1 - C_6 -alkylcarbonylamino, hydroxy, cyano, nitro, amino, N- (C_1-C_6) -alkylamino, N,N- (C_1-C_6) -dialkylamino, carboxy, sulfo, sulfamoyl, sulfonylamino, (C_1-C_6) alkylaminosulfonyl or (C_1-C_6) alkylsulfonylamino; or wherein the phenyl ring is substituted by two neighbouring residues, which together with the phenyl ring to which they are attached form tetrahydronaphthyl; wherein each alkyl is optionally substituted with hydroxy or amino;

provided that the compound is not 2-[4-[(chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, 3-[4-[(chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine, 3-[5-[(chroman-2-yl)methylamino]pentyl]-2,4-

dioxothiazolidine, 3-[6-[(chroman-2-yl)methylamino]hexyl]-2,4-dioxothiazolidine, 2-[4-[2-(phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole or 3-[4-[2-(phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine.

5 In a preferred embodiment, R_3 is preferably selected from the group consisting of chroman-2-yl, 2-quinolyl and -O-phenyl, wherein the phenyl residue is optionally substituted by a group chosen from C_1 - C_6 -alkoxy, C_1 - C_6 -alkyl, or halogen.

10 The present invention comprises three main embodiments:

- (1) m is 1 and R_3 is optionally substituted chroman-2-yl
- (2) m is 2 and R_3 is optionally substituted O-phenyl
- (3) m is 1 and R_3 is optionally substituted 2-quinolyl

15

According to a first preferred main embodiment of the present invention, m is 1 and R_3 is chroman-2-yl, the phenyl ring of which is unsubstituted or substituted by one or more groups chosen from C_1 - C_6 -alkoxy, C_1 - C_6 -alkyl, halogen, C_2 - C_6 -alkenyl, halo- (C_1-C_6) -alkyl, halo- (C_1-C_6) -alkoxy, phenyl, phenyl(C_1 - C_6)-alkyl, phenoxy, C_1 - C_6 -alkylcarbonyl, phenylcarbonyl, phenyl(C_1 - C_6)alkylcarbonyl, C_1 - C_6 -alkoxycarbonyl, phenyl(C_1 - C_6)alkoxycarbonyl, C_1 - C_6 -alkylcarbonylamino, hydroxy, cyano, nitro, amino, N- (C_1-C_6) -alkylamino, N,N- (C_1-C_6) -dialkylamino, carboxy, sulfo, sulfamoyl, sulfonylamino, (C_1-C_6) alkylaminosulfonyl or (C_1-C_6) alkylsulfonylamino; wherein each alkyl is optionally substituted with hydroxy or amino. R_3 is preferably unsubstituted chroman-2-yl.

25

Unless specifically mentioned otherwise the term "chroman-2-yl" refers to an unsubstituted chroman-2-yl residue.

30

According to a first embodiment of this first preferred main embodiment of the invention, R_1 and R_2 are methylene groups bound together forming with the heterocyclic ring a 5- or 6- membered ring and R_4 is N.

35

Those compounds wherein m is 1 and R_3 is chroman-2-yl, R_1 and R_2 are methylene groups bound together forming with the heterocyclic ring a 5- or 6- membered ring; R_4 is N; and X is selected from the group consisting of C_2 - C_{10} -

alkyl, (*E*)-2-butenyl, 3-methylbenzyl or 4-methylbenzyl are preferred.

5 In a second embodiment of this first preferred main embodiment of the present invention, R₁ is H; R₂ is absent; R₄ is S; m is 1; R₃ is chroman-2-yl; and X is selected from the group consisting of C₂-C₁₀-alkyl, C₂-C₁₀-alkenyl, or -CH₂-Y-CH₂-, wherein Y is phenyl. In one embodiment n is preferably 0.

10 In a more preferred embodiment of the present invention, it provides compounds of formula (I) wherein: R₁ is H; R₂ is absent; R₄ is S; m is 1; R₃ is chroman-2-yl; and X is C₂-C₁₀-alkyl. In one embodiment n is preferably 0.

15 A second preferred main embodiment of the invention relates to compounds wherein m is 2 and R₃ is -O-phenyl optionally substituted by one or more groups chosen from C₁-C₆-alkoxy, C₁-C₆-alkyl, halogen, C₂-C₆-alkenyl, halo-(C₁-C₆)-alkyl, halo-(C₁-C₆)-alkoxy, phenyl, phenyl(C₁-C₆)-alkyl, phenoxy, C₁-C₆-alkylcarbonyl, phenylcarbonyl, phenyl(C₁-C₆)alkylcarbonyl, C₁-C₆-alkoxycarbonyl, phenyl(C₁-C₆)alkoxycarbonyl; C₁-C₆-alkylcarbonylamino, hydroxy, cyano, nitro, amino, N-(C₁-C₆)-alkylamino, N,N-(C₁-C₆)-dialkylamino, carboxy, sulfo, sulfamoyl, sulfonylamino, (C₁-C₆)alkylaminosulfonyl or (C₁-C₆)alkylsulfonylamino; or wherein the phenyl ring is substituted by two neighbouring residues, which together with the phenyl ring to which they are attached form tetrahydronaphthyl; wherein each alkyl is optionally substituted with hydroxy or amino.

25 According to a more preferred embodiment of the second main embodiment of the invention, it relates to compounds of formula (I) wherein: m=2 and R₃ is -O-phenyl, wherein the phenyl ring is substituted by one or more groups chosen from phenyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylcarbonylamino, C₁-C₆-alkoxy, C₁-C₆-alkyl, halo-(C₁-C₆)-alkyl, or halogen or wherein the phenyl group is substituted by two neighbouring residues, which together with the phenyl group to which they are attached form tetrahydronaphthyl.

35 In another preferred embodiment, m=2 and R₃ is -O-phenyl, wherein the phenyl ring is substituted by one or more groups chosen from C₁-C₆-alkoxy, C₁-C₆-alkyl, or halogen.

Most preferred compounds are those wherein the phenyl residue is

optionally substituted by one or more groups chosen from methoxy, ethoxy, propoxy, isopropoxy, ethyl, propyl, isopropyl, bromide, trifluoromethyl, methylamide or ethoxycarbonyl.

- 5 Particularly preferred are those compounds wherein the phenyl residue is substituted in *ortho* and/or *meta* position.

10 According to a preferred embodiment of this second preferred embodiment of the invention, R₁ and R₂ are methylene groups bound together forming with the heterocyclic ring a 5- or 6- membered ring; and R₄ is N.

15 Particularly preferred compounds are those wherein R₁ and R₂ are methylene groups bound together forming with the heterocyclic ring a 5-membered ring; R₄ is N; n is 0; X is C₂-C₁₀-alkyl; m is 2; R₃ is -O-phenyl optionally substituted by one or more groups chosen from phenyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylcarbonylamino, C₁-C₆-alkoxy, C₁-C₆-alkyl, halo-(C₁-C₆)-alkyl, or halogen or wherein the phenyl group is substituted by two neighbouring residues, which together with the phenyl group to which they are attached form tetrahydronaphthyl.

20

 In a more specific embodiment R₃ is O-phenyl substituted by a group chosen from C₁-C₆-alkoxy, C₁-C₆-alkyl, or halogen.

25 In another preferred embodiment of this second preferred main embodiment of the invention, R₁ is H, R₂ is absent and R₄ is S. Particularly those wherein X is C₂-C₁₀-alkyl and n is 0.

30 According to a third main embodiment of the present invention, it relates to compounds of formula (I) wherein m is 1 and R₃ is 2-quinolyl, the aromatic ring of which is unsubstituted or substituted by one or more groups chosen from C₁-C₆-alkoxy, C₁-C₆-alkyl, halogen, C₂-C₆-alkenyl, halo-(C₁-C₆)-alkyl, halo-(C₁-C₆)-alkoxy, phenyl, phenyl(C₁-C₆)-alkyl, phenoxy, C₁-C₆-alkylcarbonyl, phenylcarbonyl, phenyl(C₁-C₆)alkylcarbonyl, C₁-C₆-alkoxycarbonyl, phenyl(C₁-C₆)alkoxycarbonyl, C₁-C₆-alkylcarbonylamino, hydroxy, cyano, nitro, amino, N-(C₁-C₆)-alkylamino, N,N-(C₁-C₆)-dialkylamino, carboxy, sulfo, sulfamoyl, sulfonylamino, (C₁-C₆)alkylaminosulfonyl or (C₁-C₆)alkylsulfonylamino; wherein each alkyl is optionally substituted with hydroxy or amino. R₃ is preferably

35

unsubstituted 2-quinolyl.

Unless specifically mentioned otherwise the term "2-quinolyl" refers to an unsubstituted quinolyl residue.

5

In a preferred embodiment of this third preferred main embodiment of the invention, R_1 and R_2 are methylene groups bound together forming with the heterocyclic ring a 5- or 6- membered ring; and R_4 is N. Those compounds wherein n is 0; and X is C_2 - C_{10} -alkyl are particularly preferred.

10

In the context of the present invention, the term "alkyl" relates to a saturated, linear or branched hydrocarbon chain. The "alkyl"-group may be unsubstituted or substituted. "Alkyl" is preferably unsubstituted. If the "alkyl" group (also as a part of e.g. phenylalkyl, alkylcarbonyl or alkoxy) is substituted, the substituents are preferably hydroxyl or amino. Unless specifically mentioned otherwise, the term "alkyl" refers to an unsubstituted hydrocarbon chain.

15

In the context of the present invention, the term " C_2 - C_{10} -alkyl" relates to a saturated, linear or branched hydrocarbon chain, that contains from 2 to 10 carbon atoms. The term " C_2 - C_{10} -alkenyl" relates to a linear or branched hydrocarbon chain that contains from 2 to 10 carbon atoms and which has at least one double bond.

20

The term " C_1 - C_6 -alkyl" relates to a saturated, linear or branched hydrocarbon chain that contains from 1 to 6 carbon atoms.

25

The term "halogen", as used in this specification, consisting of fluorine, chloride, bromide, and iodine.

30

The term "halo- (C_1-C_6) -alkyl" refers to " C_1 - C_6 alkyl" as defined above, which is substituted with at least one halogen atom. It includes as preferred embodiments difluoromethyl and trifluoromethyl.

35

The term " (C_1-C_6) -alkoxy" refers to the group $-O-(C_1-C_6)$ -alkyl.

The term "halo- (C_1-C_6) -alkoxy" refers to " C_1 - C_6 alkoxy" as defined above, which is substituted with at least one halogen atom. It includes as preferred

embodiments difluoromethoxy and trifluoromethoxy.

The term 5-HT_{1A} receptor "modulator" as used herein includes pure and partial agonists as well as antagonists of the serotonin 5-HT_{1A} receptor. Preferred are "agonists", i.e. compounds with at least partial agonistic activity at the 5-HT_{1A} receptor.

The compounds of the present invention can include enantiomers depending on their asymmetry or diastereoisomers. It is also possible stereoisomerism with regard to double bonds, thereby in some cases the molecule can exist as the (*E*) isomer or the (*Z*) isomer. Each of the different possible enantiomers, diastereoisomers or isomers with regard to double bonds and the mixtures thereof, their racemic and optically pure forms are included in the scope of the present invention.

Optically pure isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.

The expression stereochemically isomeric forms, as used in this specification, defines all the possible isomeric forms wherein the compounds of formula (I) can be present. Unless otherwise mentioned or indicated, the chemical name of the compounds designates the mixture of all the possible stereochemically isomeric forms, said mixtures containing all the diastereoisomers and enantiomers of the basic molecular structure.

When used hereinafter in this specification, the expression compounds of formula (I) has the object of also including the pharmaceutically acceptable acid addition salts and all the stereoisomeric forms.

The pharmaceutically acceptable acid addition salts previously mentioned in this specification have the object of comprising the acid addition salts that can be conveniently obtained by treatment of the base form of the compounds of formula (I) with appropriate inorganic acids such as hydrochloride or hydrobromic acids, sulphuric, nitric, phosphoric acid and analogous acids; or organic acids, such as, e.g. acetic, hydroxyacetic, propionic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulphonic, ethanesulphonic, benzenesulphonic, *p*-

toluenesulphonic, cyclamic, salicylic, *p*-aminosalicylic, palmoic acids and analogues. Inversely, said forms of acid addition salts can become the free base forms due to treatment with an appropriate base.

5 The expression acid "addition salt" comprises amorphous as well as crystalline salts and also comprises the hydrates and the forms of solvent addition that the compounds of formula (I) may form. Examples of said forms are hydrates, alcoholates and analogues.

10 In the field of the present invention physiologically compatible salts will be preferable.

General method of preparation of the compounds of the present invention:

15

A solution of 1.3 mmol of corresponding halogenated derivative dissolved in 5 mL of dry acetonitrile is added dropwise to 2.0 mmol of the corresponding alkylamine, dissolved in 2 mL of dry acetonitrile. The reaction mixture is heated to 60°C with stirring for 4-6 hours (t.l.c.). After cooling, the solvent is removed at reduced pressure, the residue is dissolved in methylene chloride (25 mL) and is washed with an aqueous solution of 20% potassium carbonate. Then, the organic phase is dried over anhydrous Na₂SO₄ and the solvent is removed at reduced pressure. The resulting oil is purified by silica gel column chromatography in the appropriate solvent mixture, producing the final product as a free base. The compound is transformed to its hydrochloride and is purified by recrystallization.

20

25

The final products have been structurally characterized by IR, NMR and quantitative elemental analysis techniques. For greater ease of handling, when the final product is not crystalline, it is transformed in a pharmaceutically acceptable salt, derived from an inorganic or organic acid.

30

Preferred compounds of the present invention are:

- 35 (a) 2-[4-[(Chroman-2(*R*)-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;
- (b) 2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine;

- (c) 2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-a]pyrazine;
- (d) 2-[5-[(Chroman-2-yl)methylamino]pentyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 5 (e) 2-[6-[(Chroman-2-yl)methylamino]hexyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (f) 2-[3-[(Chroman-2-yl)methylamino]propyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (g) 3-[8-[(Chroman-2-yl)methylamino]octyl]-2,4-dioxothiazolidine;
- 10 (h) 2-[4-[(Chroman-2(S)-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (i) 2-[8-[(Chroman-2-yl)methylamino]octyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (j) 2-[3-[[[(Chroman-2-yl)methylamino]methyl]benzyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 15 2-[4-[[[(Chroman-2-yl)methylamino]methyl]benzyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (k) 2-[4-[[[(Chroman-2-yl)methylamino]methyl]benzyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (l) (E)-2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 20 (m) 2-[4-[2-(*o*-Methoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (n) 2-[4-[2-(*m*-Methoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (o) 2-[4-[2-(*o*-Bromophenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 25 (p) 2-[4-[2-(*m*-Bromophenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (q) 2-[4-[2-(*o*-Ethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 30 (r) 2-[4-[2-(*m*-Ethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (s) 2-[4-[2-(*o*-Isopropylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (t) 2-[4-[(2-quinolyl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 35 (u) 2-[4-[2-(*o*-Ethoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;

- (v) 2-[4-[2-(*o*-Isopropoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;
- (w) 2-[4-[2-[*m*-(Trifluoromethyl)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;
- 5 (x) 2-[4-[2-(1,1'-Biphenyl-2-yloxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;
- (y) 2-[4-[2-(*o*-(Acetylamino)phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;
- (z) 2-[4-[2-[*m*-(Acetylamino)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;
- 10 (aa) 2-[4-[2-(*o*-(Ethoxycarbonyl)phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;
- (bb) 2-[4-[2-(5,6,7,8-tetrahydronaphth-1-yloxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;
- 15 (cc) 2-[4-[2-(2,3-Dimethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;
- (dd) 2-[4-[(Chroman-2-yl)methylamino]butyl]-1,4-dioxoperhydropyrido[1,2-*a*]pyrazine;
- (ee) (*Z*)-2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,4-dioxoperhydropyrrolo[1,2-*c*]imidazole;
- 20 (ff) 3-[4-[2-(*o*-Ethoxyphenoxy)ethylamino]butyl]-2,4-dioxothiazolidine;
- (gg) 3-[6-[2-(*o*-Ethoxyphenoxy)ethylamino]hexyl]-2,4-dioxothiazolidine;
- (hh) 3-[8-[2-(*o*-Ethoxyphenoxy)ethylamino]octyl]-2,4-dioxothiazolidine;
- (ii) 2-[4-[2-(*o*-Ethoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine;
- 25 (jj) 2-[6-[2-(*o*-Ethoxyphenoxy)ethylamino]hexyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine;
- (kk) 2-[4-[(2-Quinoly)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine;
- 30 (ll) 2-[6-[(2-Quinoly)methylamino]hexyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine;

their stereochemically isomer forms, hydrates, solvates and pharmaceutically acceptable salts thereof.

35

The cellular death produced by oxygen and glucose deprivation in primary cultures of rat hippocampal neurons is a model that has a much closer

similarity with cerebral infarction than the cellular death caused by serum deprivation in the culture medium. Whilst in this last model, the death, of an apoptotic nature, takes place due to the elimination of the trophic factors from the medium, oxygen and glucose deprivation causes a death with similar characteristics to that which takes place in an ischemic stroke. In accordance with the predictive value of these in vitro studies, the compound (a) of PCT/ES03/00394 only exercises a protective effect against cerebral infarction induced by permanent occlusion of the middle cerebral artery in rats at a dose of 2 mg/kg. On the other hand, as is indicated further on in the present specification, compound (e) disclosed herein, with a neuroprotective effect equal to (-)-BAYx3702 and about four times greater than the compound (a) of the previous document against death due to anoxia, significantly reduces the volume of cortical infarction in the same focal ischemia model in the rat at a much lower accumulated dose, 0.04 mg/kg, similar to the effective dose of (-)-BAYx3702 in this model.

Taking into account its 5-HT_{1A} receptor affinity and its neuroprotective capacity, the compounds of formula (I) are useful in the treatment and/or prevention of pathological states wherein the 5-HT_{1A} receptor modulators and particularly agonists are indicated, such as, for example, the treatment and/or prophylaxis of cerebral damage caused by thromboembolic stroke or traumatic brain damage, as well as the treatment and/or prevention of Parkinson's disease, depression including particularly endogenous "major" depression, migraine, pain, psychosis such as e.g. schizophrenia; mood disorders, such as anxiety disorders (e.g. obsessional compulsive disorders, generalised anxiety) and aggressive disorders (including mixed aggressive-anxiety/depressive disorders); urinary tract disorders, in particular urinary incontinence, e.g. stress incontinence.

Therefore, according to a second aspect of the present invention, it relates to a pharmaceutical composition that comprises a therapeutically effective quantity of any of the compounds of formula (I) together with a pharmaceutically acceptable carrier.

A third aspect of the present invention relates to the use of compounds of formula (I) in the manufacture of a medicament for the treatment and/or prophylaxis of Parkinson's disease, of the cerebral damage caused by

thromboembolic stroke or traumatic brain damage, depression, migraine, and/or pain, psychosis (e.g. schizophrenia); mood disorders, such as anxiety disorders (e.g. obsessional compulsive disorders, generalised anxiety) and aggressive disorders (including mixed aggressive-anxiety/depressive disorders); urinary tract disorders (e.g. incontinence).

This third aspect may alternatively be formulated as a method for treatment of the diseases mentioned above in a human comprising administering to a human in need thereof an effective amount of pharmaceutical product as described herein.

For ease of administration, the compounds of the present invention can be formulated in various pharmaceutical forms. As appropriate compositions, one can cite all the compositions usually used for drugs administered systemically or locally and externally. To prepare the pharmaceutical compositions of this invention, a therapeutically effective quantity of the particular compound, optionally in the form of an acid addition salt, as an active ingredient, is combined in an intimate mixture with a pharmaceutically acceptable carrier, which can have a large variety of forms, depending on the form of preparation desired to be administered. These pharmaceutical compositions are desirably found in the form of an appropriate unit dose, preferably for oral or rectal administration or by parenteral injection.

For example, in the preparation of the compositions in the form of an oral dose, any of the usual pharmaceutically acceptable carrier can be used, such as, e.g. water buffered and/or isotonic aqueous solutions, glycols, oils, alcohols and analogues in the case of liquid oral preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, ligands, disintegrating agents and analogues, in the case of powders, pills, capsules and tablets.


Due to their ease of administration, tablets and capsules represent the most advantageous oral unit dose form, in which case solid pharmaceutical carriers are evidently used. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, although other ingredients can be included, e.g. to favour solubility. Injectable solutions, for example, can be prepared wherein the carrier comprises saline solution, glucose solution or a

mixture of saline solution and glucose solution. Also, if suitable the compounds of the present invention may be also administered transdermally.

The present invention is illustrated with the following non-limiting examples.

EXAMPLES

Example 1. 2-[4-[(Chroman-2(R)-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (diastereoisomers) (a).



Chromatography: ethyl acetate.

Yield: 35%.

¹H-NMR (CDCl₃, δ): 1.47-1.86 (m, 5H, -(CH₂)₂-, H₇), 1.91-2.12 (m, 4H, 2H₃, 2H₆), 2.16-2.34 (m, 1H, H₇), 2.64-2.92 (m, 6H, 2CH₂NH, 2H₄), 3.16-3.28 (m, 1H, H₅), 3.48 (t, J = 7.1 Hz, 2H, NCH₂), 3.66 (dt, J = 11.2, 7.3 Hz, 1H, H₅), 4.05 (dd, J = 9.1, 7.3 Hz, 1H, H_{7a}), 4.11-4.18 (m, 1H, H₂), 6.81 (t, J = 7.6 Hz, 2H, H₈), 7.00-7.10 (m, 2H, H₅, H₇).


¹³C-NMR (CDCl₃, δ): 24.6 (C₃), 25.6 (C₄), 25.8 (CH₂), 26.9 (CH₂), 27.1 (C₆), 27.5 (C₇), 38.7 (NCH₂), 45.4 (C₅), 49.3 (CH₂CH₂NH), 54.1 (HNCH₂CH), 63.2 (C_{7a}), 75.0 (C₂), 116.7 (C₈), 120.1 (C₆), 121.9 (C_{4a}), 127.1 (C₇), 129.4 (C₅), 154.5 (C_{8a}), 160.8 (C₃), 173.9 (C₁).

Analysis calculated for C₂₀H₂₇N₃O₃.HCl:

C, 60.98; H, 7.16; N, 10.67

Found: C, 60.15; H, 7.14; N, 10.45

Example 2. 2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-a]pyridine, (b).



Chromatography: ethyl acetate.

Yield: 30%.


¹H-NMR (CDCl₃, δ): 1.06-1.40 (m, 3H, H_{6ax}, H_{7ax}, H_{8ax}), 1.60-1.62 (m, 7H, H_{6ec}, -(CH₂)₂, 2H₃), 1.88-2.09 (m, 1H, H_{7ec}), 2.11-2.18 (m, 1H, H_{8ec}), 2.71-2.74 (m, 4H, 2NHCH₂), 2.85-2.87 (m, 3H, H_{5ax}, 2H₄), 3.47 (t, 2H, J = 6.6 Hz, NCH₂), 3.67 (dd, 1H, J = 11.9, 4.3 Hz, H_{8a}), 4.03-4.14 (m, 2H, H_{5ec}, H₂), 6.76 (t, 2H, J = 7.6 Hz, H₆, H₈), 6.98 (t, 2H, J = 6.3 Hz, H₅, H₇).

Analysis calculated for C₂₁H₂₉N₃O₃·HCl·H₂O:

C, 59.21; H, 7.57; N, 9.87

Found: C, 58.76; H, 7.01; N, 9.89

Example 3. 2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-a]pyrazine, (c).



Chromatography: ethyl acetate.

Yield: 35%.

¹H-NMR (CDCl₃, δ): 1.14-2.09 (m, 9H, -(CH₂)₂, 2H₇, H₈, 2H₃), 2.28-2.34 (m, 1H, H₈), 2.65-2.93 (m, 6H, 2NHCH₂, 2H₄), 3.29-3.56 (m, 4H, NCH₂, 2H₆), 3.71 (d, 1H, J = 11.9 Hz, H₃), 4.04-4.14 (m, 3H, H₃, H_{8a}, H₂), 6.67-6.80 (m, 2H, H₆, H₈), 6.95-7.22 (m, 2H, H₅, H₇).


¹³C-NMR (CDCl₃, δ): 22.8 (C₇), 24.7, 25.0, 25.7, 26.7, 29.0 (-(CH₂)₂, C₈, C₃, C₄), 45.4 (NCH₂), 46.0 (C₆), 49.4 (NHCH₂), 51.9 (C₃), 54.0 (NHCH₂), 59.2 (C_{8a}), 74.7 (C₂), 116.9 (C₈), 120.4 (C₆), 122.1 (C_{4a}), 127.4 (C₇), 129.7 (C₅), 154.6 (C_{8a}), 163.4 (C₄), 167.4 (C₁).

Analysis calculated for C₂₁H₂₉N₃O₃·HCl·2H₂O:

C, 56.81; H, 7.72; N, 9.46

Found: C, 56.73; H, 7.09; N, 9.55

Example 4. 2-[5-[(Chroman-2-yl)methylamino]pentyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (d).



Chromatography: ethyl acetate.

Yield: 32%.

10 ¹H-NMR (CDCl₃, δ): 1.34-1.39 (m, 2H, -(CH₂)₂-), 1.61-1.76 (m, 6H, -(CH₂)₂-, 2H₃), 2.01-2.10 (m, 3H, 2H₆, H₇), 2.17-2.33 (m, 1H, H₇), 2.75-2.78 (m, 4H, CH₂CH₂NH, HNCH₂CH), 2.81-2.94 (m, 2H, 2H₄), 2.93-2.98 (m, 1H, H₅), 3.45 (t, J = 7.1 Hz, 2H, NCH₂), 3.58-3.78 (m, 1H, H₅), 4.06 (dd, J = 9.1, 7.3 Hz, 1H, H_{7a}), 4.29-4.39 (m, 1H, H₂'), 6.82-6.89 (m, 2H, H₆', H₈'), 7.02-7.11 (m, 2H, H₅, H₇).


15 ¹³C-NMR (CDCl₃, δ): 23.6 (CH₂), 24.9 (C₃'), 25.1 (C₄'), 26.9 ((CH₂)₂), 27.2 (C₆), 27.4 (C₇), 38.0 (NCH₂), 38.5 (C₅), 45.3 (CH₂CH₂NH), 47.9 (HNCH₂CH), 63.3 (C_{7a}), 70.9 (C₂), 117.1 (C₈'), 121.0 (C₆'), 121.2 (C_{4'a}), 127.4 (C₅'), 129.3 (C₇'), 153.0 (C_{8'a}), 160.7 (C₃), 173.9 (C₁).

20 Analysis calculated for C₂₁H₂₉N₃O₃·HCl·H₂O:

C, 59.21; H, 7.57; N, 9.87

Found: C, 59.19; H, 7.17; N, 9.64

25 Example 5. 2-[6-[(Chroman-2-yl)methylamino]hexyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (e).



Chromatography: chloroform/methanol, 9.5:0.5.

Yield: 35%.

35 ¹H-NMR (CDCl₃, δ): 1.28-1.35 (m, 4H, -(CH₂)₂-), 1.60-1.80 (m, 6H, -(CH₂)₂-, 2H₃), 1.96-2.14 (m, 3H, 2H₆, H₇), 2.17-2.33 (m, 1H, H₇), 2.77-3.03 (m, 6H, CH₂CH₂NH, HNCH₂CH, 2H₄'), 3.17-3.30 (m, 1H, H₅), 3.45 (t, J = 7.1 Hz, 2H, NCH₂), 3.58-3.78 (m, 1H, H₅), 4.06 (dd, J = 9.1, 7.3 Hz, 1H, H_{7a}), 4.29-4.39 (m, 1H, H₂'), 6.80-6.93 (m, 2H, H₆', H₈'), 7.00-7.08 (m, 2H, H₅, H₇).


^{13}C -NMR (CDCl_3 , δ): 24.1 (CH_2), 24.3 (C_3), 25.5 (C_4), 26.3, 26.5, 27.0 ($(\text{CH}_2)_3$), 27.5 (C_6), 27.8 (C_7), 38.7 (NCH_2), 45.5 (C_5), 49.2 ($\text{CH}_2\text{CH}_2\text{NH}$), 53.1 (HNCH_2CH), 63.3 (C_{7a}), 72.7 (C_2), 116.9 (C_8), 120.4 (C_6), 121.7 ($\text{C}_{4'a}$), 127.3 (C_5), 129.5 (C_7), 154.1 ($\text{C}_{8'a}$), 160.9 (C_3), 174.0 (C_1).

5 Analysis calculated for $\text{C}_{22}\text{H}_{31}\text{N}_3\text{O}_3 \cdot \text{HCl} \cdot \text{H}_2\text{O}$:

C, 60.06; H, 7.79; N, 9.55

Found: C, 60.46; H, 7.41; N, 9.54

10 Example 6. 2-[3-[(Chroman-2-yl)methylamino]propyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (f).



15

Chromatography: ethyl acetate.

Yield: 40%.

20 ^1H -NMR (CDCl_3 , δ): 1.64-2.32 (m, 8H, $-(\text{CH}_2)_7$, 2H_6 , 2H_7 , 2H_3), 2.68-2.88 (m, 6H, $2\text{CH}_2\text{NH}$, 2H_4), 3.18-3.30 (m, 1H, H_5), 3.58 (t, 2H, $J = 6.8$ Hz, NCH_2), 3.65-3.70 (m, 1H, H_5), 4.03-4.17 (m, 2H, H_{7a} , H_2), 6.79-6.86 (m, 2H, H_6 , H_8), 7.02-7.11 (m, 2H, H_5 , H_7).


25 ^{13}C -NMR (CDCl_3 , δ): 24.6 (C_3), 25.6 (C_4), 26.9 (CH_2), 27.5 (C_6), 28.1 (C_7), 36.9 (NCH_2), 45.5 (C_5), 46.9 ($\text{CH}_2\text{CH}_2\text{NH}$), 54.0 (HNCH_2CH), 63.3 (C_{7a}), 74.9 (C_2), 116.8 (C_8), 120.2 (C_6), 122.0 ($\text{C}_{4'a}$), 127.2 (C_7), 129.5 (C_5), 154.6 ($\text{C}_{8'a}$), 160.9 (C_3), 174.0 (C_1).

Analysis calculated for $\text{C}_{19}\text{H}_{25}\text{N}_3\text{O}_3 \cdot \text{HCl}$:

C, 60.07; H, 6.90; N, 11.06

Found: C, 59.65; H, 6.91; N, 10.55

30 Example 7. 3-[8-[(Chroman-2-yl)methylamino]octyl]-2,4-dioxothiazolidine, (g).



35

Chromatography: ethyl acetate.

Yield: 35%; m.p. 108-111 °C.

¹H-NMR (CDCl₃, δ): 1.29-1.31 (m, 8H, -(CH₂)₄-), 1.55-1.66 (m, 4H, CH₂, 2H_{3'}), 1.71-1.86 (m, 2H, CH₂), 2.70-2.93 (m, 6H, 2NHCH₂, 2H_{4'}), 3.60 (t, J = 7.6 Hz, 2H, NCH₂), 3.94 (s, 2H, 2H₅), 4.19-4.25 (m, 2H, H_{2'}, NH), 6.80-6.86 (m, 2H, H_{6'}, H_{8'}), 7.01-7.11 (m, 2H, H_{5'}, H_{7'}).


¹³C-NMR (CDCl₃, δ): 24.3, 25.4, 26.4, 26.9, 27.3, 28.8, 28.9, 29.0 (-(CH₂)₆-, C_{3'}, C_{4'}), 33.5 (C₅), 41.9 (NCH₂), 49.3, 53.3 (2CH₂NH), 74.0 (C_{2'}), 116.6 (C_{8'}), 120.2 (C_{6'}), 121.7 (C_{4a'}), 127.1 (C_{7'}), 129.3 (C_{5'}), 154.2 (C_{8a'}), 171.3, 171.7 (C₂, C₄).

Analysis calculated for C₂₁H₃₀N₂O₃S.HCl·3H₂O:

C, 52.43; H, 7.75; N, 5.82

Found: C, 52.33; H, 6.78; N, 5.79

Example 8. 2-[4-[(Chroman-2(S)-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (diastereoisomers) (h).



Chromatography: ethyl acetate.

20 Yield: 38%.

[α]²⁵_D = +65 (c = 0.5, CHCl₃).


Analysis calculated for C₂₁H₃₀N₂O₃S.HCl·3H₂O:

C, 53.62; H, 7.65; N, 9.38

Found: C, 53.45; H, 7.34; N, 9.45

25

Example 9. 2-[8-[(Chroman-2-yl)methylamino]octyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (i).



Chromatography: ethyl acetate.


35 Yield: 35%.

¹H-RMN (CDCl₃, δ): 1.29-1.31 (m, 8H, -(CH₂)₄-), 1.55-1.88 (m, 7H, -(CH₂)₂-, 2H_{3'}, H₇), 1.94-2.34 (m, 3H, 2H₆, H₇), 2.54 (br s, 1H, NH), 2.66-2.97 (m, 6H,

2CH₂NH, 2H_{4'}), 3.18-3.29 (m, 1H, H₅), 3.44 (t, 2H, *J* = 7.3 Hz, NCH₂), 3.62-3.74 (m, 1H, H₅), 4.06 (dd, 1H, *J* = 7.8, 7.6 Hz, H_{7a}); 4.14-4.21 (m, 1H, H_{2'}), 6.80-6.86 (m, 2H, H_{6'}, H_{8'}), 7.01-7.11 (m, 2H, H_{5'}, H_{7'}).

¹³C-RMN (CDCl₃, δ): 24.6, 25.7, 26.6, 27.0, 27.1, 27.6, 27.9, 29.0 (-(CH₂)₆-, C_{3'}, C_{4'}), 29.3 (C₆), 29.6 (C₇), 39.0 (NCH₂), 45.5 (C₅), 49.8 (CH₂CH₂NH), 54.0 (HNCH₂CH), 63.3 (C_{7a}), 74.7 (C_{2'}), 116.8 (C_{8'}), 121.2 (C_{6'}), 121.9 (C_{4'a}), 127.2 (C_{5'}), 129.5 (C_{7'}), 154.5 (C_{8'a}), 160.9 (C₃), 174.0 (C₁).

Example 10. 2-[3-[[[(Chroman-2-yl)methylamino]methyl]benzyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (j).



Chromatography: ethyl acetate.

Yield: 40%.

¹H-RMN (CDCl₃, δ): 1.58-2.26 (m, 6H, 2H₆, 2H₇, 2H_{3'}), 2.69-2.96 (m, 4H, CH₂NH, 2H_{4'}), 3.23 (ddd, 1H, *J* = 12.5, 7.6, 5.4 Hz, H₅), 3.69 (dt, 1H, *J* = 11.2, 7.6 Hz, H₅), 3.85 (s, 2H, CH₂Ar), 4.04-4.22 (m, 2H, H_{7a}, H₂), 4.62 (s, 2H, NCH₂), 6.82 (t, 2H, *J* = 6.8 Hz, H_{6'}, H_{8'}), 7.02-7.11 (m, 2H, H_{5'}, H_{7'}), 7.26-7.34 (m, 4H, ArH).


¹³C-RMN (CDCl₃, δ): 24.7 (C_{3'}), 25.6 (C_{4'}), 27.0 (C₆), 27.5 (C₇), 42.5 (NCH₂), 45.5 (C₅), 53.5, 53.6 (2CH₂NH), 63.4 (C_{7a}), 75.2 (C₂), 116.8 (C_{8'}), 120.2 (C_{6'}), 122.0 (C_{4'a}), 127.0, 127.2, 127.7, 128.2, 128.8 (C_{7'}, phenyl), 129.5 (C_{5'}), 136.1, 140.7 (phenyl), 154.7 (C_{8'a}), 160.5 (C₃), 173.6 (C₁).

Analysis calculated for C₂₄H₂₇N₃O₃·HCl·3H₂O:

C, 58.12; H, 6.91; N, 8.47

Found: C, 58.19; H, 6.51; N, 8.07

Example 11. 2-[4-[[[(Chroman-2-yl)methylamino]methyl]benzyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (k).



Chromatography: ethyl acetate.

Yield: 44%.

¹H-RMN (CDCl₃, δ): 1.57-2.29 (m, 6H, 2H₆, 2H₇, 2H₃), 2.75-2.95 (m, 4H, CH₂NH, 2H₄), 3.24 (ddd, 1H, J = 12.4, 7.3, 5.4 Hz, H₅), 3.69 (dt, 1H, J = 11.2, 7.6 Hz, H₅), 3.84 (s, 2H, CH₂Ar), 4.04-4.22 (m, 2H, H_{7a}, H₂'), 4.61 (s, 2H, NCH₂), 6.82 (t, 2H, J = 8.1 Hz, H₆', H₈'), 7.01-7.11 (m, 2H, H₅', H₇'), 7.28-7.38 (m, 4H, ArH).


Analysis calculated for C₂₄H₂₇N₃O₃·HCl·2H₂O:

C, 60.31; H, 6.75; N, 8.79

Found: C, 60.71; H, 6.40; N, 8.52

Example 12. (E)-2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (I).

15



Chromatography: ethyl acetate.

20 Yield: 43%.

¹H-RMN (CDCl₃, δ): 1.63-2.31 (m, 6H, 2H₆, 2H₇, 2H₃), 2.65-2.93 (m, 4H, CH₂NH, 2H₄), 3.17-3.31 (m, 3H, CH₂NH, H₅), 3.67 (dt, 1H, J = 11.2, 7.6 Hz, H₅), 4.03-4.14 (m, 4H, NCH₂, H_{7a}, H₂'), 5.54-5.85 (m, 2H, CH=CH), 6.77-6.85 (m, 2H, H₆', H₈'), 7.00-7.10 (m, 2H, H₅', H₇').

25 ¹³C-RMN (CDCl₃, δ): 24.7 (C₃'), 25.7 (C₄'), 27.1 (C₆), 27.6 (C₇), 40.2 (NCH₂), 45.6 (C₅), 50.9, 53.6 (2CH₂NH), 63.5 (C_{7a}), 75.1 (C₂), 116.8 (C₈'), 120.3 (C₆'), 122.1 (C_{4'a}), 124.8 (CH), 127.3 (C_{7'}), 129.6 (C_{5'}), 132.3 (CH), 154.6 (C_{8'a}), 160.4 (C₃), 173.6 (C₁).


Analysis calculated for C₂₀H₂₅N₃O₃·HCl·4H₂O:

30 C, 51.78; H, 7.39; N, 9.06

Found: C, 52.16; H, 7.00; N, 9.16

35

Example 13. 2-[4-[2-(*o*-Methoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole (m).



Chromatography: ethyl acetate.

10 Yield: 38%.

¹H-RMN (CDCl₃, δ): 1.63-1.71 (m, 5H, -(CH₂)₂-, H₇), 1.99-2.29 (m, 3H, 2H₆, H₇), 2.78 (t, 2H, J = 6.8 Hz, CH₂NH), 3.01-3.10 (m, 2H, CH₂NH), 3.21 (ddd, 1H, J = 11.2, 6.1, 5.6 Hz, H₅), 3.57-3.80 (m, 3H, NCH₂, H₅), 3.83 (s, 3H, OCH₃), 4.00-4.18 (m, 3H, OCH₂, H_{7a}), 6.87-6.90 (m, 4H, ArH).

15 ¹³C-RMN (CDCl₃, δ): 25.5, 25.6 (-(CH₂)₂-), 26.5, 27.4 (C₆, C₇), 38.4 (NCH₂), 45.4 (C₅), 48.1, 48.6 (2CH₂NH), 63.2 (C_{7a}), 67.7 (OCH₃), 71.0 (OCH₂), 111.8 (C_{6'}), 120.9 (C_{4'}), 125.9, 129.7 (C_{3'}, C_{5'}), 130.5 (C_{2'}), 147.8 (C_{1'}), 160.6 (C₃), 173.9 (C₁).


Analysis calculated for C₁₉H₂₇N₃O₄·HCl·4H₂O:

20 C, 48.56; H, 7.72; N, 8.94

Found: C, 48.16; H, 7.32; N, 8.48

Example 14. 2-[4-[2-(*m*-Methoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole, (n).

25



30

Chromatography: ethyl acetate.

Yield: 38%.

35 ¹H-RMN (CDCl₃, δ): 1.42-1.70 (m, 4H, -(CH₂)₂-), 1.95-2.06 (m, 3H, 2H₆, H₇), 2.10-2.19 (m, 1H, H₇), 2.64 (t, 2H, J = 6.8 Hz, CH₂NH), 2.92 (t, 2H, J = 5.4 Hz, CH₂NH), 3.16 (ddd, 1H, J = 11.2, 7.3, 5.4 Hz, H₅), 3.39 (t, 2H, J = 6.3 Hz,

NCH₂), 3.59 (dt, 1H, *J* = 11.3, 7.6 Hz, H₅), 3.71 (s, 3H, OCH₃), 3.97-4.07 (m, 3H, OCH₂, H_{7a}), 6.41-6.47 (m, 3H, H_{2'}, H_{4'}, H_{6'}), 7.10 (t, 1H, *J* = 7.8 Hz, H₅).


¹³C-RMN (CDCl₃, δ): 25.8 (-(CH₂)₂-), 27.0, 27.5 (C₆, C₇), 38.7 (NCH₂), 45.6 (C₅), 48.3, 49.0 (2CH₂NH), 63.2 (C_{7a}), 67.2, 68.6 (OCH₃, OCH₂), 101.0 (C_{2'}), 106.4, 106.6 (C_{4'}, C_{6'}), 129.8 (C_{5'}), 138.9 (C_{1'}), 160.0 (C_{3'}), 160.8 (C_{3'}), 173.9 (C₁).

Analysis calculated for C₁₉H₂₇N₃O₄·HCl·3H₂O:

C, 50.49; H, 7.58; N, 9.30

Found: C, 50.71; H, 7.18; N, 8.90

Example 15. 2-[4-[2-(*o*-Bromophenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole, (*o*).



Chromatography: ethyl acetate.

Yield: 48%; m.p. 98-99 °C.

¹H-RMN (CDCl₃, δ): 1.46-1.69 (m, 4H, -(CH₂)₂-), 1.98-2.20 (m, 4H, 2H₆, 2H₇), 2.70 (t, 2H, *J* = 6.8 Hz, CH₂NH), 3.00 (t, 2H, *J* = 5.1 Hz, CH₂NH), 3.19 (ddd, 1H, *J* = 11.2, 7.3, 5.4 Hz, H₅), 3.46 (t, 2H, *J* = 7.1 Hz, NCH₂), 3.64 (dt, 1H, *J* = 11.2, 7.6 Hz, H₅), 3.99-4.12 (m, 3H, OCH₂, H_{7a}), 6.80 (dt, 2H, *J* = 8.1, 8.0 Hz, H_{4'}, H_{6'}), 7.21 (td, 1H, *J* = 5.9, 1.2 Hz, H_{5'}), 7.49 (dd, 1H, *J* = 7.8, 1.4 Hz, H_{3'}).


¹³C-RMN (CDCl₃, δ): 25.6, 26.8 (-(CH₂)₂-), 26.9, 27.4 (C₆, C₇), 38.6 (NCH₂), 45.4 (C₅), 48.2, 48.9 (2CH₂NH), 63.1 (C_{7a}), 68.4 (OCH₂), 112.2 (C_{2'}), 113.4 (C_{6'}), 121.9 (C_{4'}), 128.3 (C_{5'}), 133.1 (C_{3'}), 155.0 (C_{1'}), 160.6 (C₃), 173.8 (C₁).

Analysis calculated for C₁₈H₂₄BrN₃O₃·HCl·2H₂O:

C, 44.78; H, 6.05; N, 8.70

Found: C, 44.38; H, 5.65; N, 9.05

Example 16. 2-[4-[2-(*m*-Bromophenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole, (*p*).



Chromatography: ethyl acetate.

Yield: 42%; m.p. 140-143 °C.

¹H-RMN (CDCl₃, δ): 1.42-1.74 (m, 4H, -(CH₂)₂-), 1.94-2.22 (m, 4H, 2H₆, 2H₇),
2.68 (t, 2H, J = 7.1 Hz, CH₂NH), 2.96 (t, 2H, J = 5.1 Hz, CH₂NH), 3.19 (ddd, 1H,
J = 11.2, 7.3, 5.1 Hz, H₅), 3.45 (t, 2H, J = 7.8 Hz, NCH₂), 3.64 (dt, 1H, J = 11.2,
7.6 Hz, H₅), 3.99-4.14 (m, 3H, OCH₂, H_{7a}), 6.78-6.83 (m, 1H, H_{4'}), 7.02-7.10 (m,
3H, H_{2'}, H_{5'}, H_{6'}).


¹³C-RMN (CDCl₃, δ): 25.6, 26.9, 27.4 (-(CH₂)₂-, C₆, C₇), 38.6 (NCH₂), 45.4 (C₅),
48.4, 49.0 (2CH₂NH), 63.2 (C_{7a}), 67.3 (OCH₂), 113.4 (C_{6'}), 117.7 (C_{2'}), 122.6
(C_{3'}), 123.8 (C_{4'}), 130.4 (C_{5'}), 159.5 (C_{1'}), 160.7 (C₃), 173.8 (C₁).

Analysis calculated for C₁₈H₂₄BrN₃O₃·HCl·2H₂O:

C, 44.78; H, 6.05; N, 8.70

Found: C, 44.47; H, 5.65; N, 9.30

- Example 17. 2-[4-[2-(*o*-Ethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole, (q).



Chromatography: chloroform/methanol, 9.5:0.5.

Yield: 28%; m.p. 115-118 °C (hexane).

¹H-RMN (CDCl₃, δ): 1.19 (t, 3H, J = 7.4 Hz, CH₃), 1.59-1.74 (m, 5H, -(CH₂)₂-,
H₇), 1.97-2.09 (m, 2H, 2H₆), 2.17-2.28 (m, 1H, H₇), 2.63 (q, 2H, J = 7.6 Hz,
CH₂CH₃), 2.80 (t, 2H, J = 7.1 Hz, CH₂NH), 3.08 (t, 2H, J = 5.1 Hz, CH₂NH),
3.17-3.29 (m, 1H, H₅), 3.50 (t, 2H, J = 6.8 Hz, NCH₂), 3.61-3.75 (m, 1H, H₅),
4.02-4.15 (m, 3H, OCH₂, H_{7a}), 6.82-6.94 (m, 2H, H_{4'}, H_{6'}), 7.11-7.17 (m, 2H, H_{3'},
H_{5'}).

¹³C-RMN (CDCl₃, δ): 12.2 (CH₃), 23.2, 25.7, 26.6 (CH₂CH₃, -(CH₂)₂-), 27.0, 27.5
(C₆, C₇), 38.6 (CH₂NCO), 45.5 (C₅), 48.5, 48.9 (2CH₂NH), 63.3 (OCH₂, C_{7a}),
111.3 (C_{6'}), 120.8 (C_{4'}), 126.8, 129.0 (C_{3'}, C_{5'}), 132.7 (C_{2'}), 156.3 (C_{1'}), 160.8
(C₃), 167.4 (C₁).


Analysis calculated for C₂₀H₂₉N₃O₃·HCl·2H₂O:

C, 55.61; H, 7.93; N, 9.73

Found: C, 55.89; H, 7.53; N, 9.81

Example 18. 2-[4-[2-(*m*-Ethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole, (r).

5



10 Chromatography: ethyl acetate.

Yield: 43%.

¹H-RMN (CDCl₃, δ): 1.24 (t, 3H, J = 7.6 Hz, CH₃), 1.59-1.74 (m, 5H, -(CH₂)₂-, H₇), 1.97-2.09 (m, 2H, 2H₈), 2.17-2.28 (m, 1H, H₇), 2.63-2.74 (m, 4H, CH₂CH₃, CH₂NH), 3.12 (t, 2H, J = 5.1 Hz, CH₂NH), 3.17-3.29 (m, 1H, H₅), 3.50 (t, 2H, J = 7.1 Hz, NCH₂), 3.61-3.75 (m, 1H, H₅), 4.02-4.15 (m, 3H, OCH₂, H_{7a}), 6.72-6.86 (m, 3H, H₂, H₄, H₆), 7.21 (t, 1H, J = 7.8 Hz, H₅).

15 ¹³C-RMN (CDCl₃, δ): 15.5 (CH₃), 25.5, 25.8, 27.0 (CH₂CH₃, -(CH₂)₂-), 27.3, 27.6 (C₆, C₇), 38.8 (NCH₂), 45.6 (C₅), 48.7, 49.0 (2CH₂NH), 63.4 (C_{7a}), 66.9 (OCH₂), 111.5 (C₂), 114.4 (C₆), 120.6 (C₄), 129.3 (C₅), 146.0 (C₃), 158.9 (C₁), 160.9 (C₃), 174.0 (C₁).


20 Analysis calculated for C₂₀H₂₉N₃O₃·HCl·H₂O:

C, 58.03; H, 7.79; N, 10.15

Found: C, 57.92; H, 7.91; N, 10.12

25 Example 19. 2-[4-[2-(*o*-Isopropylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole, (s).

30



Chromatography: ethyl acetate.


Yield: 23%.

35 ¹H-RMN (CDCl₃, δ): 1.21 (d, 6H, J = 7.9 Hz, 2CH₃), 1.44-1.76 (m, 5H, -(CH₂)₂-, H₇), 1.95-2.32 (m, 3H, 2H₈, H₇), 2.71 (t, 2H, J = 6.8 Hz, CH₂NH), 3.02 (t, 2H, J = 5.1 Hz, CH₂NH), 3.17-3.37 (m, 2H, CH, H₅), 3.49 (t, 2H, J = 7.1 Hz, NCH₂), 3.67

(dt, 1H, $J = 7.6, 3.9$ Hz, H_5), 4.00-4.09 (m, 3H, OCH_2 , H_{7a}), 6.82-6.96 (m, 2H, $H_{4'}$, $H_{6'}$), 7.09-7.22 (m, 2H, $H_{3'}$, $H_{5'}$).

^{13}C -RMN ($CDCl_3$, δ): 22.7 (CH_3), 25.9, 26.9, 27.0, 27.3, 27.6 ($-(CH_2)_2-$, CH, C_6 , C_7), 38.8 (NCH_2), 45.6 (C_5), 49.0, 49.2 ($2CH_2NH$), 63.4 (C_{7a}), 67.5 (OCH_2),
 5 111.5 (C_6), 120.8 ($C_{4'}$), 126.1, 126.6 ($C_{3'}$, C_5'), 135.3 (C_2'), 157.5 ($C_{1'}$), 160.8 (C_3), 173.9 (C_1).

Example 20. 2-[4-[(2-Quinoly)l)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-
 10 c]imidazole, (t).



15 Chromatography: ethyl acetate.


Yield: 33%; m.p. 125-126 °C

IR ($CHCl_3$, cm^{-1}): 1770, 1708 (CONCON), 1601, 1504, 1442, 1416 (Ar).

1H -RMN ($CDCl_3$, δ): 1.52-1.67 (m, 5H, $-(CH_2)_2-$, H_7), 1.90-2.27 (m, 3H, $2H_6$, H_7),
 2.50 (t, 2H, $J = 6.3$ Hz, CH_2NH), 3.01-3.24 (m, 1H, H_5), 3.42 (t, 2H, $J = 6.8$ Hz,
 20 NCH_2), 3.53-3.69 (m, 1H, H_5), 3.91-4.00 (m, 3H, CH_2Ar , H_{7a}), 7.47 (t, $J = 7.1$
 Hz, 1H, H_6), 7.62-7.77 (m, 3H, H_3 , H_5 , H_7), 8.02 (d, $J = 8.3$ Hz, 1H, $H_{4'}$), 8.11
 (d, $J = 8.5$ Hz, 1H, H_8).

^{13}C -RMN ($CDCl_3$, δ): 24.4, 25.8, 26.8, 27.4 ($2CH_2$, C_6 , C_7), 38.7 (NCH_2), 45.4
 (C₅), 53.8, 54.1 (CH_2Ar , CH_2NH), 63.1 (C_{7a}), 120.9 (C_3), 126.0 (C_6), 127.2,
 25 127.4 (C_5 , C_8), 128.9, 129.2 ($C_{4'}$, C_7), 130.7 ($C_{4'a}$), 155.9 (C_2), 160.5 ($C_{8'a}$),
 160.7 (C_3), 173.8 (C_1).

Example 21. 2-[4-[2-(*o*-Ethoxyphenoxy)ethylamino]butyl]-1,3-
 30 dioxoperhydropyrrolo[1,2-c]imidazole, (u).



35


Chromatography: ethyl acetate.

Yield: 30%.

¹H-RMN (CDCl₃, δ): 1.43 (t, 3H, *J* = 6.8 Hz, CH₃), 1.62-1.72 (m, 5H, -(CH₂)₂-, H₇), 1.94-2.27 (m, 3H, 2H₆, H₇), 2.78 (t, 2H, *J* = 6.6 Hz, CH₂NH), 3.06 (t, 2H, *J* = 5.1 Hz, CH₂NH), 3.22 (ddd, 1H, *J* = 12.4, 7.3, 5.1 Hz, H₅), 3.44-3.72 (m, 3H, NCH₂, H₅), 4.01-4.17 (m, 4H, OCH₂, H_{7a}, CH₂CH₃), 6.87-6.92 (m, 4H, ArH).

¹³C-RMN (CDCl₃, δ): 14.8 (CH₃), 25.6, 26.4, 26.8, 27.4 (-(CH₂)₂-, C₆, C₇), 38.5 (NCH₂), 45.4 (C₅), 48.3, 48.7 (2CH₂NH), 63.2 (C_{7a}), 64.3 (CH₂CH₃), 68.3 (OCH₂), 113.6, 115.1, 120.9, 121.8 (C₆, C₄, C₃, C₅), 148.3 (C₂), 149.1 (C₁), 160.7 (C₃), 173.8 (C₁).

Example 22. 2-[4-[2-(*o*-Isopropoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole, (v).



Chromatography: ethyl acetate.

Yield: 23%.

¹H-RMN (CDCl₃, δ): 1.33 (d, 6H, *J* = 6.1 Hz, 2CH₃), 1.55-1.71 (m, 4H, -(CH₂)₂-), 2.04-2.26 (m, 4H, 2H₆, 2H₇), 2.72 (q, 2H, *J* = 6.2 Hz, CH₂NH), 3.02 (q, 2H, *J* = 5.1 Hz, CH₂NH), 3.23 (ddd, 1H, *J* = 12.5, 7.3, 5.1 Hz, H₅), 3.48 (t, 2H, *J* = 6.8 Hz, NCH₂), 3.67 (dt, 1H, *J* = 11.0, 7.8 Hz, H₅), 4.02-4.13 (m, 3H, OCH₂, H_{7a}), 4.45 (sept, 1H, *J* = 6.1 Hz, CH), 6.89-6.92 (m, 4H, ArH).


¹³C-RMN (CDCl₃, δ): 22.1, 22.2 (CH₃), 25.8, 27.0, 27.5 (-(CH₂)₂-, C₆, C₇), 38.7 (NCH₂), 45.5 (C₅), 48.7, 49.0 (2CH₂NH), 63.3 (C_{7a}), 68.7 (OCH₂), 72.1 (OCH), 115.5, 116.7, 117.6, 121.8 (C₆, C₄, C₃, C₅), 145.5 (C₂), 151.2 (C₁), 160.3 (C₃), 173.9 (C₁).

Analysis calculated for C₂₀H₂₉N₃O₃·HCl·H₂O:

C, 58.03; H, 7.79; N, 10.15

Found: C, 57.92; H, 7.91; N, 10.12

Example 23. 2-[4-[2-[*m*-(Trifluoromethyl)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole, (w).



Chromatography: ethyl acetate/ethanol, 9:1.

10 Yield: 30%.


¹H-RMN (CDCl₃, δ): 1.50-1.72 (m, 5H, -(CH₂)₂-, H₇), 1.91-2.21 (m, 3H, 2H₆, H₇), 2.72 (t, 2H, *J* = 6.8 Hz, CH₂NH), 3.01 (t, 2H, *J* = 5.2 Hz, CH₂NH), 3.11-3.22 (m, 1H, H₅), 3.42 (t, 2H, *J* = 6.8 Hz, NCH₂), 3.58-3.67 (m, 1H, H₅), 3.96-4.29 (m, 3H, OCH₂, H_{7a}), 7.05-7.17 (m, 3H, H₂, H₄, H₆), 7.32 (t, 1H, *J* = 7.9 Hz, H₅).

15 Analysis calculated for C₁₉H₂₄F₃N₃O₃.HCl.H₂O:

C, 50.28; H, 6.00; N, 9.26

Found: C, 50.62; H, 6.10; N, 8.75

20 Example 24. 2-[4-[2-(1,1'-Biphenyl-2-yloxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole, (x).



Chromatography: ethyl acetate/ethanol, 9:1.

Yield: 35%.

30 ¹H-RMN (CDCl₃, δ): 1.22-1.77 (m, 4H, -(CH₂)₂-), 1.93-2.08 (m, 3H, 2H₆, H₇), 2.16-2.30 (m, 1H, H₇), 2.57 (t, 2H, *J* = 7.0 Hz, CH₂NH), 2.95 (t, 2H, *J* = 5.1 Hz, CH₂NH), 3.12-3.21 (m, 1H, H₅), 3.37 (t, 2H, *J* = 7.0 Hz, NCH₂), 3.53-3.62 (m, 1H, H₅), 3.96-4.05 (m, 3H, OCH₂, H_{7a}), 6.79-7.00 (m, 2H, ArH), 7.18-7.47 (m, 7H, ArH).


35 ¹³C-RMN (CDCl₃, δ): 25.7, 26.9, 27.0, 27.5 (-(CH₂)₂-, C₆, C₇), 38.7 (NCH₂), 45.5 (C₅), 48.5, 48.9 (2CH₂NH), 63.3 (C_{7a}), 68.1 (OCH₂), 113.3 (C₆), 121.3 (C₄), 126.9, 128.6 (C₃, C₅), 127.9, 129.5, 130.8 (5CH-Ph), 131.4 (C₂), 138.5 (C-Ph), 155.7 (C₁), 160.8 (C₃), 173.9 (C₁).

Analysis calculated for $C_{24}H_{29}N_3O_3 \cdot HCl \cdot 6H_2O$:

C, 52.21; H, 7.67; N, 7.61

Found: C, 52.61; H, 7.27; N, 8.01

- 5 Example 25. 2-[4-[2-[o-(Acetylamino)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (y).



- 15 Chromatography: ethyl acetate/ethanol, 9:1.

Yield: 24%.

- ¹H-RMN ($CDCl_3$, δ): 1.60-1.71 (m, 5H, $-(CH_2)_2-$, H_7), 1.96-2.17 (m, 3H, $2H_6$, H_7), 2.21 (s, 3H, CH_3), 2.78 (t, 2H, $J = 6.9$ Hz, CH_2NH), 3.09 (t, 2H, $J = 4.9$ Hz, CH_2NH), 3.14-3.26 (m, 1H, H_5), 3.43 (t, 2H, $J = 7.1$ Hz, NCH_2), 3.62 (dt, 1H, $J = 11.2$, 7.8 Hz, H_5), 3.93-4.19 (m, 3H, OCH_2 , H_{7a}), 6.82-6.99 (m, 3H, ArH), 8.14 (dd, 1H, $J = 7.3$, 1.7 Hz, ArH), 8.68 (br s, 1H, NH).


- 20 ¹³C-RMN ($CDCl_3$, δ): 24.6 (CH_3), 25.2, 25.3, 26.9, 27.4 ($-(CH_2)_2-$, C_6 , C_7), 38.0 (NCH_2), 45.3 (C_5), 47.7, 48.2 ($2CH_2NH$), 63.2 (C_{7a}), 66.8 (OCH_2), 112.2 (C_6'), 121.5, 121.7 (C_3' , C_4'), 124.0 (C_5'), 128.1 (C_2'), 147.4 (C_1'), 160.6 (C_3), 169.0 (CONH), 173.9 (C_1).

Analysis calculated for $C_{20}H_{28}N_4O_4 \cdot HCl \cdot 3H_2O$:

C, 50.15; H, 7.37; N, 11.70

Found: C, 50.55; H, 7.75; N, 11.98

- 30 Example 26. 2-[4-[2-[m-(Acetylamino)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (z).



Chromatography: ethyl acetate/methanol, 9:1.

Yield: 31%.

¹H-RMN (CDCl₃, δ): 1.60-1.72 (m, 5H, -(CH₂)₂-, H₇), 1.96-2.15 (m, 3H, 2H₆, H₇), 2.21 (s, 3H, CH₃), 2.82 (t, 2H, J = 6.1 Hz, CH₂NH), 3.08 (t, 2H, J = 5.8 Hz, CH₂NH), 3.19 (ddd, 1H, J = 11.2, 7.6, 5.1 Hz, H₅), 3.44 (t, 2H, J = 6.9 Hz, NCH₂), 3.62 (dt, 1H, J = 11.2, 7.8 Hz, H₅), 4.00-4.10 (m, 3H, OCH₂, H_{7a}), 4.54 (br s, 1H, NH), 6.54-6.57 (m, 1H, ArH), 6.97-7.19 (m, 3H, ArH).


¹³C-RMN (CDCl₃, δ): 24.7 (CH₃), 25.4, 25.9, 27.2, 27.6 (-(CH₂)₂-, C₆, C₇), 38.5 (NCH₂), 45.6 (C₅), 48.6, 48.8 (2CH₂NH), 63.5 (C_{7a}), 65.6 (OCH₂), 106.8 (C_{2'}), 110.2 (C_{6'}), 113.1 (C_{4'}), 129.9 (C_{5'}), 138.6 (C_{3'}), 158.7 (C_{1'}), 160.9 (C₃), 169.4 (CONH), 174.2 (C₁).

Analysis calculated for C₂₀H₂₈N₄O₄·HCl·3H₂O:

C, 50.15; H, 7.37; N, 11.70

Found: C, 50.65; H, 7.65; N, 12.03

Example 27. 2-[4-[2-[o-(Ethoxycarbonyl)phenoxy]ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (aa).



Chromatography: ethyl acetate/ethanol, 9:1.

Yield: 25%.

¹H-RMN (CDCl₃, δ): 1.39 (t, J = 7.2 Hz, CH₃CH₂), 1.66-1.83 (m, 5H, -(CH₂)₂-, H₇), 1.94-2.45 (m, 5H, 2H₆, H₇, CH₂NH), 3.15-3.27 (m, 3H, CH₂NH, H₅), 3.44-3.54 (m, 2H, NCH₂), 3.66 (dt, 1H, J = 11.2, 7.6 Hz, H₅), 4.07 (dd, 1H, J = 9.0, 7.3 Hz, H_{7a}), 4.33 (q, 2H, J = 7.1 Hz, CH₃CH₂), 4.54 (t, 2H, J = 4.6 Hz, OCH₂), 7.01-7.11 (m, 2H, ArH), 7.50 (td, 1H, J = 7.8, 1.7 Hz, ArH), 7.84 (dd, 1H, J = 7.8, 1.5 Hz, ArH).

¹³C-RMN (CDCl₃, δ): 14.0 (CH₃CH₂), 22.9, 24.8, 26.9, 27.4 (-(CH₂)₂-, C₆, C₇), 37.5 (NCH₂), 45.3 (C₅), 47.3, 47.4 (2CH₂NH), 61.5 (CH₃CH₂), 63.2 (C_{7a}), 65.7


(OCH₂), 116.2 (C_{6'}), 120.2 (C_{2'}), 122.3 (C_{4'}), 131.6 (C_{3'}), 134.4 (C_{5'}), 158.0 (C_{1'}), 160.4 (C₃), 166.6 (COO), 173.8 (C₁).

Analysis calculated for C₂₁H₂₉N₃O₅.HCl.3H₂O:

C, 51.06; H, 7.35; N, 8.51

5 Found: C, 51.36; H, 7.42; N, 8.68

Example 28. 2-[4-[2-(5,6,7,8-Tetrahydronaphth-1-yloxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (bb).



Chromatography: ethyl acetate/ethanol, 9:1.

Yield: 32%.

¹H-RMN (CDCl₃, δ): 1.52-1.77 (m, 9H, -(CH₂)₄-, H₇), 1.98-2.15 (m, 2H, 2H₆), 2.17-2.29 (m, 1H, H₇), 2.64-2.78 (m, 6H, CH₂NH, 2CH₂Ar), 3.01 (t, J = 5.1 Hz, CH₂NH), 3.17-3.29 (m, 1H, H₅), 3.49 (t, 2H, J = 7.1 Hz, NCH₂), 3.65 (dt, 1H, J = 11.2, 7.6 Hz, H₅), 4.02-4.10 (m, 3H, OCH₂, H_{7a}), 6.57 (d, 1H, J = 8.1 Hz, ArH), 6.62 (d, 1H, J = 7.6 Hz, ArH), 7.03 (t, 1H, J = 7.8 Hz, ArH).


¹³C-RMN (CDCl₃, δ): 22.8, 23.1, 25.8, 27.0, 27.2, 27.6 (-(CH₂)₂-, -(CH₂)₄-, C₆, C₇), 38.8 (NCH₂), 45.5 (C₅), 48.8, 49.1 (2CH₂NH), 63.3 (C_{7a}), 67.1 (OCH₂), 107.9 (C_{2'}), 121.6 (C_{4'}), 125.6 (C_{3'}), 126.1 (C_{8'a}), 138.6 (C_{4'a}), 156.5 (C_{1'}), 160.8 (C₃), 173.9 (C₁).

Analysis calculated for C₂₂H₃₁N₃O₃.HCl.3H₂O:

C, 55.51; H, 8.05; N, 8.83

30 Found: C, 55.18; H, 7.77; N, 8.90

Example 29. 2-[4-[2-(2,3-Dimethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, (cc).



Chromatography: ethyl acetate/methanol, 9:1.

Yield: 30%.

¹H-RMN (CDCl₃, δ): 1.53-1.73 (m, 5H, -(CH₂)₂-, H₇), 1.98-2.23 (m, 3H, 2H₆, H₇), 2.14 (s, 3H, CH₃), 2.27 (s, 3H, CH₃), 2.72 (t, 2H, J = 6.8 Hz, CH₂NH), 3.02 (t, 2H, J = 4.9 Hz, CH₂NH), 3.17-3.29 (m, 1H, H₅), 3.49 (t, 2H, J = 6.8 Hz, NCH₂), 3.67 (dt, 1H, J = 11.2, 7.6 Hz, H₅), 4.02-4.10 (m, 3H, OCH₂, H_{7a}), 6.70 (d, 1H, J = 8.3 Hz, ArH), 6.77 (d, 1H, J = 7.6 Hz, ArH), 7.03 (t, 1H, J = 7.8 Hz, ArH).


¹³C-RMN (CDCl₃, δ): 11.7, 20.1 (2CH₃), 25.9, 27.0, 27.2, 27.6 (-(CH₂)₂-, C₆, C₇), 38.8 (NCH₂), 45.6 (C₅), 49.0, 49.2 (2CH₂NH), 63.4 (C_{7a}), 67.7 (OCH₂), 109.2 (C_{6'}), 122.4 (C_{4'}), 125.8 (C_{5'}), 137.9, 138.1 (C_{2'}, C_{3'}), 155.9 (C_{1'}), 160.5 (C₃), 173.9 (C₁).

Analysis calculated for C₂₀H₂₉N₃O₃·HCl·3H₂O:

C, 53.38; H, 8.06; N, 9.34

Found: C, 52.99; H, 8.15; N, 9.74

Example 30. 2-[4-[(Chroman-2-yl)methylamino]butyl]-1,4-dioxoperhydropyrido[1,2-a]pyrazine, (dd).



Chromatography: ethyl acetate.

Yield: 35%.

¹H-RMN (CDCl₃, δ): 1.40-1.68 (m, 8H, -(CH₂)₂-, 2H₇, H_{8ax}, H_{9ax}), 1.96-2.07 (m, 3H, H_{8ec}, 2H_{3'}), 2.33-2.58 (m, 2H, H_{9ec}, H_{6ax}), 2.70-2.96 (m, 6H, 2NHCH₂, 2H_{4'}), 3.41 (t, 2H, J = 6.6 Hz, NCH₂), 3.82 (d, 2H, J = 11.7 Hz, H_{9a}), 3.96 (s, 2H, 2H₃), 4.14-4.19 (m, 1H, H_{2'}), 4.67 (d, 1H, J = 12.9 Hz, H_{6ec}), 6.83 (t, 2H, J = 7.6 Hz, H_{6'}, H_{8'}), 7.02-7.11 (m, 2H, H_{5'}, H_{7'}).


¹³C-RMN (CDCl₃, δ): 24.2, 24.4, 24.6, 25.6, 26.9 (-(CH₂)₂-, C₇, C₈, C_{3'}, C_{4'}), 31.3 (C₉), 42.4 (C₆), 45.7 (NCH₂), 49.2, 49.3 (NHCH₂, C₃), 54.0 (NHCH₂), 59.2 (C_{9a}), 74.8 (C_{2'}), 116.8 (C_{8'}), 120.2 (C_{6'}), 122.0 (C_{4a'}), 127.2 (C_{7'}), 129.5 (C_{5'}), 154.4 (C_{8a'}), 161.3 (C₄), 164.9 (C₁).

Analysis calculated for C₂₂H₃₁N₃O₃·HCl·H₂O:

C, 60.06; H, 7.79; N, 9.55

Found: C, 60.23; H, 7.43; N, 9.22

Example 31. (Z)-2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,4-dioxopiperidino[1,2-c]imidazole, (ee).



Chromatography: ethyl acetate.

Yield: 38%.

¹H-RMN (CDCl₃, δ): 1.59-2.32 (m, 6H, 2H₆, 2H₇, 2H_{3'}), 2.70-2.86 (m, 4H, CH₂NH, 2H₄), 3.24 (ddd, 1H, J = 11.2, 7.6, 5.4 Hz, H₅), 3.50 (d, 2H, J = 6.6 Hz, CH₂NH), 3.68 (dt, 1H, J = 11.2, 7.8 Hz, H₅), 4.03-4.19 (m, 4H, NCH₂, H_{7a}, H_{2'}), 5.47-5.57 (m, 1H, CH), 5.70-5.82 (m, 1H, CH), 6.79-6.86 (m, 2H, H_{6'}, H_{8'}), 7.02-7.07 (m, 2H, H_{5'}, H₇).


¹³C-RMN (CDCl₃, δ): 24.5, 25.4, 26.8, 27.3 (C_{3'}, C_{4'}, C₆, C₇), 35.7 (NCH₂), 45.3, 45.9 (C₅, CH₂NH), 53.6 (CH₂NH), 63.2 (C_{7a}), 75.0 (C₂), 116.6 (C_{8'}), 119.9 (C_{6'}), 121.8 (C_{4'a}), 124.3 (CH), 127.0 (C_{7'}), 129.3 (C_{5'}), 132.7 (CH), 155.8 (C_{8a}), 156.2 (C₃), 172.4 (C₁).

Analysis calculated for C₂₀H₂₅N₃O₃·HCl·4H₂O:

C, 51.78; H, 7.39; N, 9.06

Found: C, 51.42; H, 7.02; N, 8.75

Example 32. 3-[4-[2-(o-Ethoxyphenoxy)ethylamino]butyl]-2,4-dioxothiazolidine, (ff).



Chromatography: ethyl acetate/ethanol, 9:1.

Yield: 55%; m.p. 70-74 °C.

¹H-RMN (CDCl₃, δ): 1.44 (t, 3H, J = 7.0 Hz, CH₃), 1.57-1.74 (m, 4H, -(CH₂)₂-), 2.83 (t, 2H, J = 7.0 Hz, CH₂NH), 3.13 (t, 2H, J = 5.0 Hz, CH₂NH), 3.29 (t, 2H, J

= 7.5 Hz, NCH₂), 3.96 (s, 2H, 2H₅), 4.08 (q, 2H, *J* = 7.0 Hz, CH₂CH₃), 4.19 (t, 2H, *J* = 5.0 Hz, OCH₂), 6.86-6.97 (m, 4H, ArH).


¹³C-RMN (CDCl₃, δ): 14.9 (CH₃), 24.0, 25.2 (-(CH₂)₂-), 33.8 (C₅), 41.6 (NCH₂), 48.2, 48.5 (2CH₂NH), 64.4 (CH₂CH₃), 68.3 (OCH₂), 113.6, 115.1, 121.0, 121.8 (C_{6'}, C_{4'}, C_{3'}, C_{5'}), 148.3, 149.1 (C_{1'}, C_{2'}), 171.3 (C₂, C₄).

Analysis calculated for C₁₇H₂₄N₂O₄S.HCl·1/2H₂O:

C, 51.31; H, 6.59; N, 7.04

Found: C, 51.36; H, 7.04; N, 6.66

Example 33. 3-[6-[2-(*o*-Ethoxyphenoxy)ethylamino]hexyl]-2,4-dioxothiazolidine, (gg).



Chromatography: ethyl acetate/ethanol, 9:1.

Yield: 48%; m.p. 92-94 °C.

¹H-RMN (CDCl₃, δ): 1.18-1.66 (m, 11H, -(CH₂)₄-, CH₃), 2.73 (t, 2H, *J* = 7.1 Hz, CH₂NH), 3.06 (t, 2H, *J* = 5.3 Hz, CH₂NH), 3.46 (br s, 1H, NH), 3.60 (t, 2H, *J* = 7.4 Hz, NCH₂), 3.92 (s, 2H, 2H₅), 4.06 (q, 2H, *J* = 7.0 Hz, CH₂CH₃), 4.15 (t, 2H, *J* = 5.0 Hz, OCH₂), 6.81-6.97 (m, 4H, ArH).


¹³C-RMN (CDCl₃, δ): 14.8 (CH₃), 26.3, 26.6, 27.3, 29.1 (-(CH₂)₄-), 33.6 (C₅), 41.9 (NCH₂), 48.4, 49.2 (2CH₂NH), 64.4 (CH₂CH₃), 68.3 (OCH₂), 113.6, 115.1, 121.0, 121.8 (C_{6'}, C_{4'}, C_{3'}, C_{5'}), 148.3, 149.1 (C_{1'}, C_{2'}), 171.3 (C₂, C₄).

Analysis calculated for C₁₉H₂₈N₂O₄S.HCl·H₂O:

C, 52.46; H, 7.18; N, 6.44

Found: C, 52.64; H, 6.99; N, 6.45

Example 34. 3-[8-[2-(*o*-Ethoxyphenoxy)ethylamino]octyl]-2,4-dioxothiazolidine, (hh).



Chromatography: ethyl acetate/ethanol, 9:1.

Yield: 48%; m.p. 105-108 °C.

¹H-RMN (CDCl₃, δ): 1.07-1.54 (m, 15H, -(CH₂)₆-, CH₃), 2.73 (t, 2H, J = 7.4 Hz, CH₂NH), 3.04 (t, 2H, J = 5.2 Hz, CH₂NH), 3.44 (br s, 1H, NH), 3.54 (t, 2H, J = 7.4 Hz, NCH₂), 3.87 (s, 2H, 2H₅), 4.01 (q, 2H, J = 7.0 Hz, CH₂CH₃), 4.13 (t, 2H, J = 5.2 Hz, OCH₂), 6.76-6.92 (m, 4H, ArH).


¹³C-RMN (CDCl₃, δ): 14.7 (CH₃), 26.4, 26.8, 27.3, 28.7, 28.8, 29.0 (-(CH₂)₆-), 33.5 (C₅), 41.9 (NCH₂), 48.1, 49.1 (2CH₂NH), 64.3 (CH₂CH₃), 68.0 (OCH₂), 113.5, 115.1, 120.9, 121.9 (C_{6'}, C_{4'}, C_{3'}, C_{5'}), 148.3, 149.2 (C_{1'}, C_{2'}), 171.3 (C₂, C₄).

Analysis calculated for C₂₁H₃₂N₂O₄S.HCl·1/2H₂O:

C, 55.55; H, 7.55; N, 6.17

Found: C, 55.78; H, 7.34; N, 6.04

Example 35. 2-[4-[2-(*o*-Ethoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-a]pyridine, (ii).



Chromatography: ethyl acetate/ethanol, 7:3.

Yield: 31%.

¹H-RMN (CDCl₃, δ): 1.28-1.74 (m, 11H, -(CH₂)₂-, CH₃, H_{6ax}, H_{7ax}, H_{8ax}, H_{6ec}), 1.94-2.03 (m, 1H, H_{7ec}), 2.14-2.21 (m, 1H, H_{8ec}), 2.73-2.87 (m, 3H, H_{5ax}, CH₂NH), 3.11 (t, 2H, J = 5.2 Hz, CH₂NH), 3.51 (t, 2H, J = 6.5 Hz, NCH₂), 3.69-3.79 (m, 1H, H_{8a}), 4.00-4.12 (m, 3H, CH₂CH₃, H_{5ec}), 4.18 (t, 2H, J = 5.1 Hz, OCH₂), 6.77-6.87 (m, 4H, ArH).


¹³C-RMN (CDCl₃, δ): 15.1 (CH₃), 22.9, 25.1, 26.0, 27.9, 29.8 (-(CH₂)₂-, C₆, C₇, C₈), 38.3 (NCH₂), 39.4 (C₅), 48.3, 48.8 (2CH₂NH), 57.5 (C_{8a}), 64.6, 68.1 (CH₂CH₃, OCH₂), 113.7, 115.4, 121.2, 122.2 (C_{6'}, C_{4'}, C_{3'}, C_{5'}), 148.3, 149.3 (C_{1'}, C_{2'}), 154.1 (C₃), 173.4 (C₁).

Analysis calculated for C₂₁H₃₁N₃O₄.HCl·H₂O:

C, 56.81; H, 7.72; N, 9.46

Found: C, 57.38; H, 8.00; N, 9.02

Example 36. 2-[6-[2-(*o*-Ethoxyphenoxy)ethylamino]hexyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine, (jj).



Chromatography: ethyl acetate/ethanol, 8:2.

10 Yield: 49%.

¹H-RMN (CDCl₃, δ): 1.23-1.63 (m, 14H, -(CH₂)₄-, CH₃, H_{6ax}, H_{7ax}, H_{8ax}), 1.71-1.75 (m, 1H, H_{6ec}), 1.96-2.01 (m, 1H, H_{7ec}), 2.18-2.22 (m, 1H, H_{8ec}), 2.70 (t, 2H, J = 7.3 Hz, CH₂NH), 2.77-2.87 (m, 1H, H_{5ax}), 3.03 (t, 2H, J = 5.3 Hz, CH₂NH), 3.48 (t, 2H, J = 7.3 Hz, NCH₂), 3.73 (dd, 1H, J = 11.9, 4.1 Hz, H_{8a}), 4.07 (q, 2H, J = 7.0 Hz, CH₂CH₃), 4.14 (t, 2H, J = 5.3 Hz, OCH₂), 4.18-4.19 (m, 1H, H_{5ec}), 6.86-7.26 (m, 4H, ArH).


15 ¹³C-RMN (CDCl₃, δ): 14.7 (CH₃), 22.6, 24.8, 26.3, 26.6, 27.6, 27.0, 29.3 (-(CH₂)₄-, C₆, C₇, C₈), 38.3 (NCH₂), 39.1 (C₅), 48.4, 49.3 (2CH₂NH), 57.1 (C_{8a}), 64.3, 68.4 (CH₂CH₃, OCH₂), 113.5, 114.9, 120.9, 121.6 (C_{6'}, C_{4'}, C_{3'}, C_{5'}), 148.3, 148.7 (C_{1'}, C_{2'}), 154.4 (C₃), 173.1 (C₁).

20 Analysis calculated for C₂₃H₃₅N₃O₄.HCl.7/2H₂O:

C, 53.43; H, 8.38; N, 8.13

Found: C, 53.18; H, 7.82; N, 7.60

25 Example 37. 2-[4-[(2-Quinoly)l)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-*a*]pyridine, (kk).



Chromatography: ethyl acetate/ethanol, 7:3.

Yield: 45%; m.p. 206-208 °C.

35 ¹H-RMN (CDCl₃, δ): 1.21-1.77 (m, 8H, -(CH₂)₂-, H_{6ax}, H_{7ax}, H_{8ax}, H_{6ec}), 1.95-1.99 (m, 1H, H_{7ec}), 2.16-2.22 (m, 1H, H_{8ec}), 2.76-2.86 (m, 3H, H_{5ax}, CH₂NH), 3.24 (br s, 1H, NH), 3.53 (t, 2H, J = 6.9 Hz, NCH₂), 3.73 (dd, 1H, J = 12.1, 4.4 Hz, H_{8a}), 4.12-4.18 (m, 3H, CH₂Ar, H_{5ec}), 7.46 (d, 1H, J = 8.4 Hz, H_{3'}), 7.44-7.54 (m, 1H,

H_{8'}), 7.67-7.73 (m, 1H, H_{7'}), 7.81 (dd, 1H, *J* = 8.2, 1.1 Hz, H_{5'}), 8.06 (d, *J* = 8.5 Hz, 1H, H_{4'}), 8.13 (d, 1H, *J* = 8.5 Hz, H_{8'}).


¹³C-RMN (CDCl₃, δ): 22.7, 24.9, 25.9, 26.3, 27.8 (-(CH₂)₂-, C₆, C₇, C₈), 38.2 (NCH₂), 39.3 (C₅), 48.7 (CH₂NH), 54.6 (CH₂Ar), 57.3 (C_{8a}), 120.4 (C_{3'}), 126.3 (C_{6'}), 127.3, 127.5 (C_{5'}, C_{8'}), 128.9, 129.6 (C_{4'}, C_{7'}), 136.7 (C_{4'a}), 147.5 (C_{8'a}), 154.5 (C_{2'}), 158.0 (C₃), 173.2 (C₁).

Analysis calculated for C₂₁H₂₆N₄O₂·2HCl·1/2H₂O:

C, 56.25; H, 6.52; N, 12.50

Found: C, 56.66; H, 6.53; N, 11.94

Example 38. 2-[6-[(2-Quinoly)methylamino]hexyl]-1,3-dioxoperhydroimidazo[1,5-a]pyridine (II).



Chromatography: ethyl acetate/methanol, 7:3.

Yield: 30%; m.p. 176-188 °C.

¹H-RMN (CDCl₃, δ): 1.19-1.74 (m, 12H, -(CH₂)₄-, H_{6ax}, H_{7ax}, H_{8ax}, H_{6ec}), 1.95-2.00 (m, 1H, H_{7ec}), 2.17-2.22 (m, 1H, H_{8ec}), 2.76 (t, 2H, *J* = 7.1 Hz, CH₂NH), 2.81-2.86 (m, 1H, H_{5ax}), 3.06 (br s, 1H, NH), 3.48 (t, 2H, *J* = 7.3 Hz, NCH₂), 3.72 (dd, 1H, *J* = 11.9, 4.3 Hz, H_{8a}), 4.14-4.19 (m, 3H, CH₂Ar, H_{5ec}), 7.46 (d, 1H, *J* = 8.5 Hz, H_{3'}), 7.49-7.55 (m, 1H, H_{6'}), 7.68-7.74 (m, 1H, H_{7'}), 7.81 (dd, 1H, *J* = 8.2, 1.1 Hz, H_{5'}), 8.06 (d, *J* = 8.5 Hz, 1H, H_{4'}), 8.13 (d, 1H, *J* = 8.4 Hz, H_{8'}).

¹³C-RMN (CDCl₃, δ): 22.7, 24.9, 26.3, 26.6, 27.8, 28.0, 29.0 (-(CH₂)₄-, C₆, C₇, C₈), 38.4 (NCH₂), 39.2 (C₅), 49.2 (CH₂NH), 54.6 (CH₂Ar), 57.2 (C_{8a}), 120.3 (C_{3'}), 126.2 (C_{6'}), 127.3, 127.5 (C_{5'}, C_{8'}), 128.9, 129.6 (C_{4'}, C_{7'}), 136.7 (C_{4'a}), 147.5 (C_{8'a}), 154.5 (C_{2'}), 158.2 (C₃), 173.2 (C₁).

Analysis calculated for C₂₃H₃₀N₄O₂·2HCl·3/2H₂O:

C, 55.87; H, 7.13; N, 11.33

Found: C, 55.77; H, 7.09; N, 10.77

Example 39. Radioligand binding assays.

The *in vitro* affinity of the compounds of the present invention for the 5-

HT_{1A}, 5-HT_{2A}, 5-HT₃, 5-HT₄, 5-HT₇, α_1 and D₂ cerebral receptors was evaluated using radioligand binding assays. The following specific ligands and tissues were used:

- 5 * 5-HT_{1A} receptors, [³H]-8-OH-DPAT, rat cerebral cortex;
- * 5-HT_{2A} receptors, [³H]ketanserin, rat cerebral cortex;
- * 5-HT₃ receptors, [³H]LY 278584, rat cerebral cortex;
- * 5-HT₄ receptors, [³H]GR 113808, rat striatum;
- * 5-HT₇ receptors, [³H]-5-CT, rat hypothalamus;
- 10 * α_1 receptors, [³H]prazosin, rat cerebral cortex;
- * D₂ receptors, [³H]spiperone, rat striatum.

Compound BAYx3702 was selected as a 5-HT_{1A} reference ligand, as well as the left-hand isomer of the same, (-)-BAYx3702.

15 For all receptor binding assays, male Sprague-Dawley rats (*Rattus norvegicus albinus*), weighing 180-200 g, were killed by decapitation and the brains rapidly removed and dissected. Tissues were stored at -80 °C for subsequent use and homogenized on a Polytron PT-10 homogenizer. Membrane suspensions were centrifuged on a Beckman J2-HS instrument.

20 The bonded radioactive ligands were separated from the free ones by vacuum filtration on Whatman GF/C filters washed twice with 4 mL of the corresponding buffer. 4 mL of liquid scintillation (EcoLite) were added and the radioactivity bonded to the membranes was measured by liquid scintillation spectrometry.

25

5-HT_{1A} receptor

30 Binding assays were performed by a modification of the procedure previously described by Clark et al. (J. Med. Chem., 1990, 33, 633), as described below.

 The cerebral cortex was homogenized in 10 volumes of ice-cold Tris buffer (50 mM Tris-HCl, pH 7.7 at 25 °C) and centrifuged at 28000g for 15 min. The membrane pellet was washed twice by resuspension and centrifugation.

35 After the second wash the resuspended pellet was incubated at 37 °C for 10 min. Membranes were then collected by centrifugation and the final pellet was resuspended in 50 mM Tris-HCl, 5 mM MgSO₄, and 0.5 mM EDTA buffer (pH

7.4 at 37 °C). Fractions of 100 µL of the final membrane suspension (about 1 mg of protein) were incubated at 37 °C for 15 min with 0.6 nM [³H]-8-OH-DPAT (133 Ci/mmol), in the presence or absence of the competing drug, in a final volume of 1.1 mL of assay buffer (50 mM Tris-HCl, 10 nM clonidine, 30 nM prazosin, pH 7.4 at 37 °C). Nonspecific binding was determined with 10 µM 5-HT.

5-HT_{2A} receptor

Binding assays were performed by a modification of the procedure previously described by Titeler et al. (Biochem. Pharmacol., 1987, 36, 3265), as described below.

The frontal cortex was homogenized in 60 volumes of ice-cold buffer (50 mM Tris-HCl, 0.5 mM Na₂EDTA, 10 mM MgSO₄, pH 7.4 at 25 °C), and centrifuged at 30000g for 15 min at 4 °C. The membrane pellet was washed by resuspension and centrifugation. After the second wash the resuspended pellet was incubated at 37 °C for 10 min. Membranes were then collected by centrifugation and the final pellet was resuspended in 10 volumes of assay buffer (50 mM Tris-HCl, 0.5 mM Na₂EDTA, 10 mM MgSO₄, 0.1% ascorbic acid, 10 µM pargyline, pH 7.4 at 25 °C). Fractions of 100 µL of the final membrane suspension (about 5 mg/mL of protein) were incubated at 37 °C for 15 min with 0.4 nM [³H]ketanserin, in the presence or absence of the competing drug, in a final volume of 2 mL of assay buffer. Nonspecific binding was determined with 1 µM cinanserin.

5-HT₃ receptor

Binding assays were performed by a modification of the procedure previously described by Wong et al. (Eur. J. Pharmacol., 1989, 166, 107), as described below.

The cerebral cortex was homogenized in 9 volumes of ice-cold 0.32 M sucrose and centrifuged at 1000g for 10 min at 4 °C. The supernatant was centrifuged at 17000g for 20 min at 4 °C. The membrane pellet was washed twice by resuspension in 60 volumes of ice-cold 50 mM Tris-HCl buffer (pH 7.4 at 25 °C) and centrifugation at 48000g for 10 min at 4 °C. After the second

5 wash the resuspended pellet was incubated at 37 °C for 10 min, and centrifuged at 48000g for 10 min at 4 °C. Membranes were resuspended in 2.75 volumes of assay buffer (50 mM Tris-HCl, 10 µM pargyline, 0.6 mM ascorbic acid, and 5 mM CaCl₂, pH 7.4 at 25 °C). Fractions of 100 µL of the final membrane suspension (about 2 mg/mL of protein) were incubated at 25 °C for 30 min with 0.7 nM [³H]LY 278584, in the presence or absence of the competing drug, in a final volume of 2 mL of assay buffer. Nonspecific binding was determined with 10 µM 5-HT.

10 5-HT₄ receptor

Binding assays were performed by a modification of the procedure previously described by Grossman et al. (Br. J. Pharmacol., 1993, 109, 618), as described below.

15

The striatum was homogenized in 15 volumes of ice-cold 50 mM HEPES buffer (pH 7.4 at 4 °C) and centrifuged at 48000g for 10 min. The pellet was resuspended in 20 volumes of assay buffer (50 mM HEPES, pH 7.4 at 25 °C). Fractions of 100 µL (about 5 mg/mL of protein) of the final membrane suspension were incubated at 37 °C for 30 min with 0.1 nM [³H]GR 113808, in the presence or absence of the competing drug, in a final volume of 1 mL of assay buffer. Nonspecific binding was determined with 30 µM 5-HT.

20

5-HT₇ receptor

25

Binding assays were performed by a modification of the procedure previously described by Aguirre et al. (Eur. J. Pharmacol., 1998, 346, 181), as described below.

30

The hypothalamus was homogenized in 5 mL of ice-cold Tris buffer (50 mM Tris-HCl, pH 7.4 at 25 °C) and centrifuged at 48000g for 10 min. The membrane pellet was washed by resuspension and centrifugation, and then the resuspended pellet was incubated at 37 °C for 10 min. Membranes were then collected by centrifugation and the final pellet was resuspended in 100 volumes of ice-cold 50 mM Tris-HCl, 4 mM CaCl₂, 1 mg/mL ascorbic acid, 0.01 mM pargyline and 3 µM pindolol buffer (pH 7.4 at 25 °C). Fractions of 400 µL of the final membrane suspension were incubated at 23 °C for 120 min. with 0.5 nM

35

5 [3H]-5-CT (88 Ci/mmol), in the presence or absence of several concentrations of the competing drug, in a final volume of 0.5 mL of assay buffer (50 mM Tris-HCl, 4 mM CaCl₂, 1 mg/mL ascorbic acid, 0.01 mM pargyline and 3 μM pindolol buffer (pH 7.4 at 25 °C)). Non-specific binding was determined with 10 μM 5-HT.

α₁ receptor

10 Binding assays were performed by a modification of the procedure previously described by Ambrosio et al. (Neurosci. Lett., 1984, 49, 193), as described below.

15 The cerebral cortex was homogenized in 20 volumes of ice-cold buffer (50 mM Tris-HCl, 10 mM MgCl₂, pH 7.4 at 25 °C) and centrifuged at 30000g for 15 min. Pellets were washed twice by resuspension and centrifugation. Final pellets were resuspended in the same buffer. Fractions of the final membrane suspension (about 250 μg of protein) were incubated at 25 °C for 30 min with 0.2 nM [3H]prazosin (23 Ci/mmol), in the presence or absence of six concentrations of the competing drug, in a final volume of 2 mL of buffer. 20 Nonspecific binding was determined with 10 μM phentolamine.

D₂ receptor

25 Binding assays were performed by a modification of the procedure previously described by Leysen et al. (Biochem. Pharmacol., 1978, 27, 307), as described below.

30 The striatum was homogenized in 50 mM Tris-HCl (pH 7.7 at 25 °C) and centrifuged at 48000g for 10 min. The pellet was resuspended and centrifuged as before. The final pellet was resuspended in 50 mM Tris-HCl (pH 7.7 at 25 °C) containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 1 mM MgCl₂, and 0.1% ascorbic acid. Fractions of the final membrane suspension (125-150 μg of protein) were incubated at 25 °C for 60 min with 0.8 nM [3H]raclopride (77 Ci/mmol), in the presence or absence of six concentrations of the competing drug, in a final volume of 1.1 mL of the assay buffer (pH 7.4 at 25 °C). 35 Nonspecific binding was determined with 1 μM (+)-butaclamol.

For all binding assays, competing drug, nonspecific, total and radioligand bindings were defined in triplicate. Incubation was terminated by rapid vacuum filtration through Whatman GF/B filters, presoaked in 0.05% poly(ethylenimine), using a Brandel cell harvester. The filters were then washed with the assay buffer, dried and placed in poly(ethylene) vials to which were added 4 mL of a scintillation cocktail (Aquasol). The radioactivity bound to the filters was measured by liquid scintillation spectrometry. The data were analyzed by an iterative curve-fitting procedure (program Prism, Graph Pad), which provided IC_{50} , K_i , and r^2 values for test compounds, K_i values being calculated from the Cheng and Prusoff equation. The protein concentrations of the rat cerebral cortex and the rat striatum were determined by the method of Lowry, using bovine serum albumin as the standard.

Results:

All the tested compounds showed a high affinity for the 5-HT_{1A} receptor with a K_i value of between 0.5 and about 100 nM. Most of the compounds bind the 5-HT_{1A} receptor with an affinity of below 30 nM. Also, most of the compounds are highly selective for the 5-HT_{1A} receptor over 5-HT_{2A}, 5-HT₃, 5-HT₄ and dopamine receptors.

Example 40. Functional characterization.

Cell culture and determination of cAMP levels after stimulation of the adenylate cyclase enzyme with forskolin.

HeLa cells transfected with the human 5-HT_{1A} receptor (HA 6 cells) were grown in 75 mL flasks containing 20 mL of Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 500 units penicillin and 500 µg streptomycin/mL (P/S) and 0.3 mg/mL geneticin. Forty-eight hours before the experiment cells were plated at a density of 75×10^3 cells in 1.5 mL of DMEM-P/S-fetal calf serum-geneticin medium in 12 multiwell plates. The day of the experiment, cells were treated with 0.5 mM 1-methyl-3-isobutylxanthine (IBMX), 10 µM forskolin, and vehicle or and different concentrations of the compounds under study in a 37 °C and 5% CO₂ incubator. Ten minutes later, treatment was stopped and cells were lysed with a 65% ethanol solution for 2 h, then the ethanol was collected and evaporated at 55 °C leaving a pellet with

5 cAMP. Samples were analyzed using a commercial radioimmunoassay (RIA) kit ([³H]cAMP assay system, cod. TRK 432; Amersham). Protein was measured by Bradford's method. Competition binding isotherms were analysed by using an iterative curve-fitting procedure (program Origin 7.0), which provided EC₅₀ values for test compounds.

10 The experiment shows that the tested compounds significantly inhibit the AMPc formation in HeLa cells, most compounds acting as pure and some as partial agonists.

Determination of the rectal temperature in mice.

15 5-HT_{1A} receptor agonists such as, for example, 8-OH-DPAT, reduce the body temperature of the rodents. This effect in the mouse seems to be due to the activation of the somatodendritic receptors (De Vry, Psychopharmacology 1995, 121, 1) since the administration for two weeks of a tryptophan hydroxylase inhibitor such as *parachlorophenylalanine* or the damage with a selective neurotoxin of serotonergic neurons such as 5,7-dihydroxytryptamine (5,7-DHT) completely blocks the hypothermic effect on mice.

20 In the test carried out with the compounds of the present invention, batches of 8-10 mice were processed, testing at least 4 doses of the compounds object under study. Animals were maintained in a temperature and light (25±1 °C, light on between 8.00 a.m. and 8.00 p.m.) controlled environment. Food and tap water were provided ad libitum. All experiments were performed between 9.00 a.m. and 2.00 p.m. The test consisted of inserting a probe into the animals rectum 1.5 cm for 40 s measuring the basal temperature, this being the 0 time of the experiment. Immediately afterwards, the compounds to be tested were administered subcutaneously (s.c) and the rectal temperature was measured after different times: 15, 30, 60, 120 and 240 minutes.

35 The experiment shows that the tested compounds are 5-HT_{1A} agonists, according to the minimum effective dose administered and the hypothermic effect obtained.

Example 41. In vitro neuroprotection studies.

Neurotoxicity induced by hypoxia / hypoglycaemia.

5 The capacity to prevent neurotoxicity induced by hypoxia /
hypoglycaemia in primary cultures of rat hippocampus (E18) was determined.
To prepare the cultures, the foetuses' brain was dissected, separating the
meninges, and the hippocampus was dispersed on a neurobasal medium
supplemented with B-27. After centrifuging at 700 g, the pellet was
10 mechanically redispersed. The density of the cellular suspension was
measured and aliquots were taken to culture on Petri dishes, previously coated
with poly-lysine, using the same medium. The culture was kept in an incubator
at 37°C in a 95% air/ 5% CO₂ atmosphere. After 10 days' culture, the dishes
were transferred, in a glucose-free medium, to a chamber wherein they were
15 kept for 2 hours in a 95% N₂/ 5% CO₂ atmosphere. Before the hypoxia, the
compounds to be studied were added at variable times and concentrations.

Neurotoxicity due to deprivation of trophic factors.

20 The prevention of cellular death with apoptotic characteristics which
results after maintaining the hippocampus cultures in a serum-free medium for
48 hours (Koh et al., Science, 1995, 268, 573) was also studied. In this case,
an Eagle medium (DMEM) modified with 10% of calf serum was initially used
and, after 10 days, the cultures were transferred to the DMEM culture deprived
25 of calf serum.

 In both cases, the measurement of the mitochondrial dehydrogenase on
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) with
subsequent colorimetric measurement of the formazan formed, which provides
30 a cell survival index (Nonaka et al., Proc. Natl. Acad. Sci. USA, 1998, 95,
2642), was considered as toxicity indexes.

The results obtained are set down in the following table 1.

Table 1.

Compound	Protection (%)	
	Serum Deprivation	Oxygen-glucose deprivation
8-OH-DPAT	44.0 ± 1.4	54.0 ± 3.5
(-)-BAYx3702	31.0 ± 2.9	77.5 ± 8.6
(±)-BAYx3702	25.9 ± 2.5	ND
a	10.7 ± 2.4	55.8 ± 12.5
b	19.0 ± 3.3	42.0 ± 7.8
c	13.0 ± 4.3	65.6 ± 4.8
d	15.5 ± 2.2	78.0 ± 6.5
e	29.6 ± 2.8	78.0 ± 6.8
f	36.0 ± 3.2	35.0 ± 7.0
g	32.0 ± 4.0	32.0 ± 8.0

Example 42. In vivo neuroprotection study.

Focal ischemic model in rats.

The intraluminal occlusion of the middle cerebral artery (MCA) in rats was performed following previously described methods (Justicia et al., J Cereb. Blood Flow Metab., 1999, 19, 128), as described below.

The rats were anaesthetised with halotan, maintaining their temperature at 37.5°C using an electric blanket connected to a rectal probe and cannulating the left femoral artery to monitor blood pressure. The right carotid artery was exposed, occluding the extra-cranial branches, and a blunt nylon filament was introduced through the external carotid until reaching the level when the middle cerebral artery (MCA) branches.

The selected compounds were administered intravenously. 24 Hours after the ischemic damage, the rats were anaesthetised with ether, they were

perfused with saline solution and were then decapitated, extracting the brains that were cut into 1.5 mm coronal slices. The slices were then incubated in 4% triphenyltetrazolium chloride (TTC), which reacts with the intact mitochondrial enzymes producing a red colour which contrasts with the paleness of the infarcted area, permitting it to be viewed, subsequently maintaining it in 10% formalin. The volume of cerebral infarction (mm^3) was calculated by measuring, in an image analyser, the affected area in the areas of cerebral cortex irrigated by the MCA and in the striatum and multiplying the average value obtained in each slice by the thickness thereof.

The intravenous infusion of 40 $\mu\text{g/Kg}$ of compound (e) for 4 hours significantly reduced the infarcted cerebral volume in the rat after intraluminal occlusion of the MCA. The effect was observed even when the rats received the compound for a period of 2 hours after the start of the MCA occlusion. The protective effect was only apparent in the cortical area but not in the subcortical area and did not cause alterations in the arterial blood pressure.

In Table 2, the values of infarcted volume both for a saline solution, and for the standard (-)-BAYx3702 and for compound (e), are set down.


Table 2.

Compound	Dose	Infarcted Volumen (mm^3)		
		Total	Cortical	Subcortical
Saline	-	546.4 ± 51.1	399.2 ± 37.5	147.2 ± 23.4
(-)-BAY x3702	40 $\mu\text{g/kg}$	$376.7 \pm 57.8 *$	$271.2 \pm 54.7 *$	105.5 ± 9.3
e	40 $\mu\text{g/kg}$	$386.7 \pm 47.1 *$	$262.7 \pm 40.9 *$	124.0 ± 14.3

* $p < 0.05$ vs. Control (saline)

CLAIMS

1. A compound of formula I:



one of their stereochemically isomer forms or a pharmaceutically acceptable salt thereof, wherein:

15 R_1 and R_2 are H or are methylene groups bound together forming with the heterocyclic ring a 5- or 6- membered ring; if $R_4=S$ then R_1 is H and R_2 is absent;

R_4 is selected from the group consisting of N and S;

n being an integer from 0 to 1;

20 X is selected from the group consisting of C_2 - C_{10} -alkyl, C_2 - C_{10} -alkenyl and $-CH_2$ - Y - CH_2 -; wherein Y is phenyl;

m being an integer from 1 to 2;

25 R_3 is selected from the group consisting of chroman-2-yl, 2-quinolyl and -O-phenyl, wherein the aromatic ring of the chromanyl moiety, the quinolyl or the phenyl residue is optionally substituted by one or more groups chosen from C_1 - C_6 -alkoxy, C_1 - C_6 -alkyl, halogen, C_2 - C_6 -alkenyl, halo- (C_1-C_6) -alkyl, halo- (C_1-C_6) -alkoxy, phenyl, phenyl(C_1-C_6)-alkyl, phenoxy, C_1 - C_6 -alkylcarbonyl, phenylcarbonyl, phenyl(C_1-C_6)alkylcarbonyl, C_1 - C_6 -alkoxycarbonyl, phenyl(C_1-C_6)alkoxycarbonyl, C_1 - C_6 -alkylcarbonylamino, hydroxy, cyano, nitro, amino, N- (C_1-C_6) -alkylamino, N,N- (C_1-C_6) -dialkylamino, carboxy, sulfo, sulfamoyl, sulfonylamino, (C_1-C_6) alkylaminosulfonyl or (C_1-C_6) alkylsulfonylamino; or
30 wherein the phenyl ring is substituted by two neighbouring residues, which together with the phenyl ring to which they are attached form tetrahydronaphthyl; wherein each alkyl is optionally substituted with hydroxy or amino;

35 provided that the compound is not 2-[4-[(chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole, 3-[4-[(chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine, 3-[5-[(chroman-2-yl)methylamino]pentyl]-2,4-

dioxothiazolidine, 3-[6-[(chroman-2-yl)methylamino]hexyl]-2,4-dioxothiazolidine, 2-[4-[2-(phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole or 3-[4-[2-(phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine.

- 5 2. Compound according to claim 1, wherein R_3 is selected from the group consisting of chroman-2-yl, 2-quinolyl and -O-phenyl, wherein the phenyl residue is optionally substituted by a group chosen from C_1 - C_6 -alkoxy, C_1 - C_6 -alkyl, or halogen;
- 10 3. Compound according to claim 1 or 2, wherein m is 1 and R_3 is chroman-2-yl.
- 15 4. Compound according to claim 3, wherein R_1 and R_2 are methylene groups bound together forming with the heterocyclic ring a 5- or 6- membered ring; and R_4 is N.
- 20 5. Compound according to any of claims 3 to 4, wherein X is selected from the group consisting of C_2 - C_{10} -alkyl, (*E*)-2-butenyl, 3-methylbenzyl or 4-methylbenzyl.
- 25 6. Compound according to claim 3, wherein R_1 is H, R_2 is absent and R_4 is S.
- 30 7. Compound according to claim 6, wherein n is 0 and X is C_2 - C_{10} -alkyl.
- 35 8. Compound according to claim 1 or 2, wherein $m=2$ and R_3 is -O-phenyl, wherein the phenyl residue is optionally substituted by one or more groups chosen from C_1 - C_6 -alkoxy, C_1 - C_6 -alkyl, halogen, C_2 - C_6 -alkenyl, halo- (C_1-C_6) -alkyl, halo- (C_1-C_6) -alkoxy, phenyl, phenyl(C_1-C_6)-alkyl, phenoxy, C_1 - C_6 -alkylcarbonyl, phenylcarbonyl, phenyl(C_1-C_6)alkylcarbonyl, C_1 - C_6 -alkoxycarbonyl, phenyl(C_1-C_6)alkoxycarbonyl, C_1 - C_6 -alkylcarbonylamino, hydroxy, cyano, nitro, amino, N- (C_1-C_6) -alkylamino, N,N- (C_1-C_6) -dialkylamino, carboxy, sulfo, sulfamoyl, sulfonylamino, (C_1-C_6) alkylaminosulfonyl or (C_1-C_6) alkylsulfonylamino; or wherein the phenyl ring is substituted by two neighbouring residues, which together with the phenyl ring to which they are attached form tetrahydronaphthyl.
9. Compound according to claim 8, wherein the phenyl group is optionally substituted by one or more groups chosen from phenyl, C_1 - C_6 -alkoxycarbonyl,

C₁-C₆-alkylcarbonylamino, C₁-C₆-alkoxy, C₁-C₆-alkyl, halo-(C₁-C₆)-alkyl, or halogen or wherein the phenyl group is substituted by two neighbouring residues, which together with the phenyl group to which they are attached form tetrahydronaphthyl.

5

10. Compound according to claim 9, wherein the phenyl residue is optionally substituted by one or more groups chosen from methoxy, ethoxy, propoxy, isopropoxy, ethyl, propyl, isopropyl, bromide, trifluoromethyl, methylamide or ethoxycarbonyl.

10

11. Compound according to any of claims 8 to 10, wherein the phenyl group is substituted in *ortho*- and/or *meta*- position.

15

12. Compound according to any of claims 8 to 11, wherein R₁ and R₂ are methylene groups bound together forming with the heterocyclic ring a 5- or 6-membered ring; and R₄ is N.

20

13. Compound according to any of claims 8 to 12, wherein n is 0 and X is C₂-C₁₀-alkyl.

14. Compound according to any of claims 8 to 11, wherein R₁ is H and R₂ is absent and R₄ is S.

25

15. Compound according to claim 14, wherein n is 0 and X is C₂-C₁₀-alkyl.

16. Compound according to claims 1 or 2, wherein m is 1 and R₃ is 2-quinolyl.

30

17. Compound according to claim 16, wherein R₁ and R₂ are methylene groups bound together forming with the heterocyclic ring a 5- or 6- membered ring; R₄ is N.

18. Compound according to any of claims 17 to 18, wherein n is 0; and X is C₂-C₁₀-alkyl.

35

19. Compound according to claim 1, wherein the compound is selected from:

(a) 2-[4-[(Chroman-2(*R*)-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-

- c]imidazole;
- (b) 2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-a]pyridine;
- (c) 2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-a]pyrazine;
- 5 (d) 2-[5-[(Chroman-2-yl)methylamino]pentyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (e) 2-[6-[(Chroman-2-yl)methylamino]hexyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 10 (f) 2-[3-[(Chroman-2-yl)methylamino]propyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (g) 3-[8-[(Chroman-2-yl)methylamino]octyl]-2,4-dioxothiazolidine;
- (h) 2-[4-[(Chroman-2(S)-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 15 (i) 2-[8-[(Chroman-2-yl)methylamino]octyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (j) 2-[3-[(Chroman-2-yl)methylamino]methyl]benzyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (k) 2-[4-[(Chroman-2-yl)methylamino]methyl]benzyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 20 (l) (E)-2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (m) 2-[4-[2-(o-Methoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 25 (n) 2-[4-[2-(*m*-Methoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (o) 2-[4-[2-(o-Bromophenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (p) 2-[4-[2-(*m*-Bromophenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 30 (q) 2-[4-[2-(o-Ethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (r) 2-[4-[2-(*m*-Ethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 35 (s) 2-[4-[2-(o-Isopropylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (t) 2-[4-[(2-quinolyl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-

- c]imidazole;
- (u) 2-[4-[2-(*o*-Ethoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (v) 2-[4-[2-(*o*-Isopropoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 5 (w) 2-[4-[2-(*m*-(Trifluoromethyl)phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (x) 2-[4-[2-(1,1'-Biphenyl-2-yloxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 10 (y) 2-[4-[2-(*o*-(Acetylamino)phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (z) 2-[4-[2-(*m*-(Acetylamino)phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (aa) 2-[4-[2-(*o*-(Ethoxycarbonyl)phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 15 (bb) 2-[4-[2-(5,6,7,8-Tetrahydronaphth-1-yloxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- (cc) 2-[4-[2-(2,3-Dimethylphenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole;
- 20 (dd) 2-[4-[(Chroman-2-yl)methylamino]butyl]-1,4-dioxoperhydropyrido[1,2-a]pyrazine;
- (ee) (Z)-2-[4-[(Chroman-2-yl)methylamino]but-2-enyl]-1,4-dioxoperhydropyrrolo[1,2-c]imidazole;
- (ff) 3-[4-[2-(*o*-Ethoxyphenoxy)ethylamino]butyl]-2,4-dioxothiazolidine;
- 25 (gg) 3-[6-[2-(*o*-Ethoxyphenoxy)ethylamino]hexyl]-2,4-dioxothiazolidine;
- (hh) 3-[8-[2-(*o*-Ethoxyphenoxy)ethylamino]octyl]-2,4-dioxothiazolidine;
- (ii) 2-[4-[2-(*o*-Ethoxyphenoxy)ethylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-a]pyridine;
- (jj) 2-[6-[2-(*o*-Ethoxyphenoxy)ethylamino]hexyl]-1,3-dioxoperhydroimidazo[1,5-a]pyridine;
- 30 (kk) 2-[4-[(2-Quinolyl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-a]pyridine;
- (ll) 2-[6-[(2-Quinolyl)methylamino]hexyl]-1,3-dioxoperhydroimidazo[1,5-a]pyridine;
- 35

a pharmaceutically acceptable salt or one of their stereochemically isomer forms.

20. Pharmaceutical composition which comprises a therapeutically effective amount of a compound as claimed in any of claims 1 to 19 and, pharmaceutically acceptable carriers.
- 5
21. Use of a compound of any of claims 1 to 19 for the preparation of a medicament for the treatment and/or prophylaxis of pathological states in which 5-HT_{1A} agonists are indicated.
- 10
22. The use according to claim 21 in the preparation of a medicament for the treatment and/or prophylaxis of Parkinson Disease, cerebral damage by thromboembolic ictus, craneoencephalic traumatism, depression, migraine, pain, psychosis, anxiety disorders, aggressive disorders or urinary tract disorders.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/000840

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D487/04 C07D417/12 C07D417/04 C07D277/34 A61K31/4188 A61K31/427		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/29687 A (JANSSEN PHARMACEUTICA N.V.; WIGERINCK, PIET, TOM, BERT, PAUL; VERSCHUER) 17 June 1999 (1999-06-17) tables F-3; compound 73	1-3, 5, 20
A	WO 03/029250 A (BAYER AKTIENGESELLSCHAFT; SCHERLING, DIETRICH; KARL, WOLFGANG; SEIDEL,) 10 April 2003 (2003-04-10) page 1, line 18 - page 2, line 3	1-22
A	EP 0 352 613 A (BAYER AG) 31 January 1990 (1990-01-31) page 2, line 9 - page 6, line 1	1-22
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family		
Date of the actual completion of the international search 19 May 2005		Date of mailing of the international search report 27/05/2005
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Usuel11, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/000840

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 2004/014915 A (CEPA SCHWARZ PHARMA S.L; DEL RIO ZAMBRANA, JOAQUIN; FRECHILLA MANSO, D) 19 February 2004 (2004-02-19) page 1, line 1 - page 1, line 22 page 3, line 18 - page 4, line 32; example all</p> <p>-----</p>	1-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2005/000840

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9929687	A	17-06-1999	AU 748669 B2	06-06-2002
			AU 2412799 A	28-06-1999
			BG 104372 A	29-12-2000
			BR 9814256 A	03-10-2000
			CA 2311669 A1	17-06-1999
			CN 1280577 A ,C	17-01-2001
			EA 3365 B1	24-04-2003
			EE 200000328 A	15-08-2001
			WO 9929687 A1	17-06-1999
			EP 1036073 A1	20-09-2000
			HR 20000340 A1	30-04-2001
			HU 0004492 A2	28-03-2002
			ID 24616 A	27-07-2000
			IL 136529 A	12-03-2003
			JP 2001525407 T	11-12-2001
			NO 20002074 A	02-06-2000
			NZ 503603 A	26-10-2001
			PL 341007 A1	12-03-2001
			SK 8032000 A3	12-02-2001
			TR 200001542 T2	22-01-2001
			TW 577886 B	01-03-2004
			UA 70308 C2	15-11-2000
			US 2003083365 A1	01-05-2003
			US 6133277 A	17-10-2000
			US 2003149093 A1	07-08-2003
			US 6495547 B1	17-12-2002
			ZA 9811081 A	22-06-2000
WO 03029250	A	10-04-2003	DE 10148425 A1	17-04-2003
			CA 2462142 A1	10-04-2003
			WO 03029250 A1	10-04-2003
			EP 1434777 A1	07-07-2004
			JP 2005507901 T	24-03-2005
			US 2004259924 A1	23-12-2004
EP 0352613	A	31-01-1990	DE 3901814 A1	01-02-1990
			AT 104668 T	15-05-1994
			AU 627478 B2	27-08-1992
			AU 3898989 A	01-02-1990
			CA 1341162 C	02-01-2001
			CN 1039809 A ,C	21-02-1990
			DD 287500 A5	28-02-1991
			DE 58907493 D1	26-05-1994
			DK 371389 A	29-01-1990
			EP 0352613 A2	31-01-1990
			ES 2052829 T3	16-07-1994
			FI 893571 A ,B,	29-01-1990
			HK 38695 A	24-03-1995
			HU 58036 A2	28-01-1992
			HU 211160 B3	30-10-1995
			IE 62704 B1	22-02-1995
			IL 91126 A	30-03-1995
			JP 2096552 A	09-04-1990
			JP 2963107 B2	12-10-1999
			KR 183006 B1	01-05-1999
			NO 892892 A ,B,	29-01-1990
			NZ 230071 A	26-03-1992
			PT 91299 A ,B	08-02-1990

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2005/000840

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0352613	A	SG 12595 G	16-06-1995
		US 5506246 A	09-04-1996
		US 5137901 A	11-08-1992
		US 5585392 A	17-12-1996
		US 5300523 A	05-04-1994
		ZA 8905713 A	25-04-1990
WO 2004014915	A	ES 2199086 A1	01-02-2004
	19-02-2004	AU 2003254512 A1	25-02-2004
		CA 2492837 A1	19-02-2004
		WO 2004014915 A1	19-02-2004